Michael R Hayden

List of Publications by Year
in descending order

765 papers	72,901 citations	435 131 h-index	1222 227 g-index
793 all docs	793 docs citations	793 times ranked	41418 citing authors

#	Article	IF	Citations
1	Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice. Neurobiology of Disease, 2022, 166, 105652.	4.4	12
2	Mutant Huntingtin Is Cleared from the Brain via Active Mechanisms in Huntington Disease. Journal of Neuroscience, 2021, 41, 780-796.	3.6	37
3	Sigma-1 Receptor (S1R) Interaction with Cholesterol: Mechanisms of S1R Activation and Its Role in Neurodegenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 4082.	4.1	24
4	The Sigma-1 Receptor Mediates Pridopidine Rescue of Mitochondrial Function in Huntington Disease Models. Neurotherapeutics, 2021, 18, 1017-1038.	4.4	28
5	Pridopidine reduces mutant huntingtinâ€induced endoplasmic reticulum stress by modulation of the Sigmaâ€1 receptor. Journal of Neurochemistry, 2021, 158, 467-481.	3.9	16
6	Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic Huntington disease mice. Neurobiology of Disease, 2021, 152, 105293.	4.4	16
7	Reliable Resolution of Full-Length Huntingtin Alleles by Quantitative Immunoblotting. Journal of Huntington's Disease, 2021, 10, 355-365.	1.9	7
8	I01â€…Orally bioavailable small molecule splicing modifiers with systemic and even htt-lowering activity in vitro and in vivo. , 2021, , .		0
9	Rescue of aberrant huntingtin palmitoylation ameliorates mutant huntingtin-induced toxicity. Neurobiology of Disease, 2021, 158, 105479.	4.4	16
10	Sigma-1 and dopamine D2/D3 receptor occupancy of pridopidine in healthy volunteers and patients with Huntington disease: a [18F] fluspidine and [18F] fallypride PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1103-1115.	6.4	28
11	Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma. Scientific Reports, 2021, 11, 21975.	3.3	8
12	Quantification of Motor Function in Huntington Disease Patients Using Wearable Sensor Devices. Digital Biomarkers, 2020, 3, 103-115.	4.4	23
13	pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model. Cell Death and Disease, 2020, 11, 809.	6.3	13
14	Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies. Lancet Neurology, The, 2020, 19, 930-939.	10.2	43
15	The Interaction of Aging and Cellular Stress Contributes to Pathogenesis in Mouse and Human Huntington Disease Neurons. Frontiers in Aging Neuroscience, 2020, 12, 524369.	3.4	21
16	Tracing the mutated HTT and haplotype of the African ancestor who spread Huntington disease into the Middle East. Genetics in Medicine, 2020, 22, 1903-1908.	2.4	8
17	Coupled Control of Distal Axon Integrity and Somal Responses to Axonal Damage by the Palmitoyl Acyltransferase ZDHHC17. Cell Reports, 2020, 33, 108365.	6.4	19
18	Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance range. Genetics in Medicine, 2020, 22, 2108-2113.	2.4	32

#	Article	IF	Citations
19	Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington disease. Human Molecular Genetics, 2020, 29, 2788-2802.	2.9	17
20	DAPK1 Promotes Extrasynaptic GluN2B Phosphorylation and Striatal Spine Instability in the YAC128 Mouse Model of Huntington Disease. Frontiers in Cellular Neuroscience, 2020, 14, 590569.	3.7	14
21	Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease. Neurobiology of Disease, 2020, 141, 104943.	4.4	11
22	Compromised IGF signaling causes caspase-6 activation in Huntington disease. Experimental Neurology, 2020, 332, 113396.	4.1	6
23	Pharmacogenomics of Vincristineâ€induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. Clinical Pharmacology and Therapeutics, 2019, 105, 402-410.	4.7	56
24	In search of a genetic explanation for LDLc variability in an FH family: common SNPs and a rare mutation in MTTP explain only part of LDL variability in an FH family. Journal of Lipid Research, 2019, 60, 1733-1740.	4.2	2
25	Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound. Cell Chemical Biology, 2019, 26, 1295-1305.e6.	5.2	10
26	Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease. Frontiers in Cellular Neuroscience, 2019, 13, 209.	3.7	41
27	Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease. American Journal of Human Genetics, 2019, 104, 1116-1126.	6.2	130
28	Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiology of Disease, 2019, 129, 118-129.	4.4	48
29	Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9622-9627.	7.1	79
30	Altered Regulation of Striatal Neuronal N-Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model. Frontiers in Synaptic Neuroscience, 2019, 11, 3.	2.5	27
31	Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease. Neurotherapeutics, 2019, 16, 465-479.	4.4	47
32	A Comprehensive Haplotype-Targeting Strategy for Allele-Specific HTT Suppression in Huntington Disease. American Journal of Human Genetics, 2019, 105, 1112-1125.	6.2	23
33	Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Research, 2019, 48, 36-54.	14.5	41
34	Pridopidine, a clinicâ€ready compound, reduces 3,4â€dihydroxyphenylalanineâ€induced dyskinesia in Parkinsonian macaques. Movement Disorders, 2019, 34, 708-716.	3.9	32
35	Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurology, The, 2019, 18, 165-176.	10.2	82
36	Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor. Neurobiology of Disease, 2019, 124, 489-504.	4.4	56

#	Article	IF	Citations
37	Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance. FASEB Journal, 2019, 33, 3190-3197.	0.5	20
38	Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease. Molecular Neurobiology, 2019, 56, 4464-4478.	4.0	27
39	The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 346-357.	1.7	60
40	Constitutive ablation of caspase-6 reduces the inflammatory response and behavioural changes caused by peripheral pro-inflammatory stimuli. Cell Death Discovery, 2018, 4, 40.	4.7	9
41	A whole brain longitudinal study in the YAC128 mouse model of Huntingtonâ€™s disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes. Human Molecular Genetics, 2018, 27, 2125-2137.	2.9	27
42	HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo. Human Molecular Genetics, 2018, 27, 239-253.	2.9	21
43	Further Investigation of the Role of ACYP2 and WFS1 Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. Clinical Cancer Research, 2018, 24, 1866-1871.	7.0	32
44	Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. Acta Neuropathologica Communications, 2018, 6, 16.	5.2	47
45	The global spectrum of protein-coding pharmacogenomic diversity. Pharmacogenomics Journal, 2018, 18, 187-195.	2.0	72
46	Genetic ablation ofCyp8b1preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E418-E432.	3.5	22
47	Characterization of subventricular zone-derived progenitor cells from mild and late symptomatic YAC128 mouse model of Huntington's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 34-44.	3.8	2
48	A43â€...Intrinsic mutant HTT-mediated defects in oligodendroglia cells contribute to myelin deficits and behavioural abnormalities in huntington disease. , 2018, , .		1
49	Huntingtin suppression restores cognitive function in a mouse model of Huntingtonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	89
50	Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Molecular Neurodegeneration, 2018, 13, 25.	10.8	26
51	Therapeutic approaches to Huntington disease: from the bench to the clinic. Nature Reviews Drug Discovery, 2018, 17, 729-750.	46.4	117
52	A human huntingtin SNP alters post-translational modification and pathogenic proteolysis of the protein causing Huntington disease. Scientific Reports, 2018, 8, 8096.	3.3	38
53	Therapeutic modulation of the bile acid pool byCyp8b1knockdown protects against nonalcoholic fatty liver disease in mice. FASEB Journal, 2018, 32, 3792-3802.	0.5	37
54	Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease. BMC Biology, 2018, 16, 58.	3.8	19

#	Article	IF	Citations
55	I09â€...Antibodies inhibit cell to cell transmission of mutant HTT. , 2018, , .		0
56	Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. Progress in Neurobiology, 2017, 152, 114-130.	5.7	29
57	Author response: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology, 2017, 88, 334-335.	1.1	0
58	Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease. Journal of Neuroscience, 2017, 37, 2776-2794.	3.6	50
59	Role of repeats in protein clearance. Nature, 2017, 545, 33-34.	27.8	4
60	Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncology, 2017, 3, 1558.	7.1	41
61	Palmitoylation of caspase-6 by HIP14 regulates its activation. Cell Death and Differentiation, 2017, 24, 433-444.	11.2	32
62	Pharmacogenomic screening for anthracyclineâ€induced cardiotoxicity in childhood cancer. British Journal of Clinical Pharmacology, 2017, 83, 1143-1145.	2.4	13
63	The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. European Journal of Human Genetics, 2017, 25, 332-340.	2.8	15
64	ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2147-2155.	2.4	55
65	A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Human Molecular Genetics, 2017, 26, ddx021.	2.9	37
66	A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Medicine, 2017, 9, 50.	8.2	25
67	eEF2K inhibition blocks AÎ²42 neurotoxicity by promoting an NRF2 antioxidant response. Acta Neuropathologica, 2017, 133, 101-119.	7.7	48
68	The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiology of Disease, 2017, 97, 46-59.	4.4	105
69	Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntingtonâ€™s Disease Models. Molecular Neurobiology, 2017, 54, 5385-5399.	4.0	105
70	Epidemiology of Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 31-46.	1.8	43
71	Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model. Annals of the New York Academy of Sciences, 2017, 1407, 75-89.	3.8	7
72	Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight, 2017, 2, .	5.0	39

#	Article	IF	Citations
73	A true mentor and pioneer in medical genetics. South African Medical Journal, 2016, 106, 7.	0.6	0
74	Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations. Pharmacogenetics and Genomics, 2016, 26, 28-39.	1.5	21
75	A novel microdeletion affecting the CETP gene raises HDLâ€associated cholesterol levels. Clinical Genetics, 2016, 89, 495-500.	2.0	0
76	Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Experimental Neurology, 2016, 283, 121-128.	4.1	26
77	B42â€...Early olfactory behaviour deficits associated with olfactory bulb atrophy and caspase-8 activation in HD rodent models. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A24.1-A24.	1.9	0
78	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinsonâ€™s disease: a pharmacogenetic study. Brain, 2016, 139, 2050-2062.	7.6	53
79	Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. Journal of Neuroimmunology, 2016, 290, 84-95.	2.3	21
80	Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. Neuroscience, 2016, 325, 74-88.	2.3	34
81	Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6145-E6152.	7.1	111
82	Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Human Molecular Genetics, 2016, 25, 3975-3987.	2.9	65
83	Recommendations for genetic testing to reduce the incidence of anthracyclineâ€induced cardiotoxicity. British Journal of Clinical Pharmacology, 2016, 82, 683-695.	2.4	188
84	Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. Journal of Neurochemistry, 2016, 137, 782-794.	3.9	30
85	An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Human Molecular Genetics, 2016, 25, 3654-3675.	2.9	85
86	Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology, 2016, 87, 282-288.	1.1	82
87	Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Scientific Reports, 2016, 6, 31652.	3.3	59
88	Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. Scientific Reports, 2016, 6, 25333.	3.3	130
89	Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. BMC Biology, 2016, 14, 108.	3.8	22
90	Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Human Molecular Genetics, 2016, 25, ddw122.	2.9	62

#	Article	IF	Citations
91	ABCA1 deficiency and cellular cholesterol accumulation increases islet amyloidogenesis in mice. Diabetologia, 2016, 59, 1242-1246.	6.3	24
92	Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Experimental Neurology, 2016, 278, 4-10.	4.1	38
93	Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. Molecular Therapy - Nucleic Acids, 2016, 5, e297.	5.1	97
94	Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. Human Molecular Genetics, 2016, 25, 1600-1618.	2.9	14
95	Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin. Neuropeptides, 2016, 58, 73-81.	2.2	28
96	Aberrant palmitoylation in Huntington disease. Biochemical Society Transactions, 2015, 43, 205-210.	3.4	27
97	696. Pre-Clinical Evaluation of Allele-Specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides. Molecular Therapy, 2015, 23, S277.	8.2	0
98	Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers. PLoS Computational Biology, 2015, 11, e1004405.	3.2	120
99	Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Scientific Reports, 2015, 5, 10191.	3.3	14
100	A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Movement Disorders, 2015, 30, 393-401.	3.9	50
101	Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression. Neuroscience Letters, 2015, 598, 66-72.	2.1	26
102	Loss of Cyp8b1 Improves Glucose Homeostasis by Increasing GLP-1. Diabetes, 2015, 64, 1168-1179.	0.6	89
103	Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development. Developmental Biology, 2015, 397, 257-266.	2.0	8
104	Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiology of Disease, 2015, 76, 24-36.	4.4	48
105	Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2015, 76, 46-56.	4.4	78
106	Biophysical and Biological Characterization of Hairpin and Molecular Beacon RNase H Active Antisense Oligonucleotides. ACS Chemical Biology, 2015, 10, 1227-1233.	3.4	12
107	Human genetics of HDL: Insight into particle metabolism and function. Progress in Lipid Research, 2015, 58, 14-25.	11.6	45
108	A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Human Molecular Genetics, 2015, 24, 2604-2614.	2.9	48

#	Article	IF	Citations
109	Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics, 2015, 16, 1065-1076.	1.3	95
110	A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature Genetics, 2015, 47, 1079-1084.	21.4	214
111	Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Research, 2015, 25, 701-713.	5.5	24
112	A SNP in the HTT promoter alters NF-Î¹B binding and is a bidirectional genetic modifier of Huntington disease. Nature Neuroscience, 2015, 18, 807-816.	14.8	113
113	Clinical Exome/Genome Reports-Announcement. Clinical Genetics, 2015, 87, 99-99.	2.0	0
114	Huntington disease. Nature Reviews Disease Primers, 2015, 1, 15005.	30.5	1,031
115	HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Human Molecular Genetics, 2015, 24, 3257-3271.	2.9	102
116	Post-translational myristoylation at the cross roads of cell death, autophagy and neurodegeneration. Biochemical Society Transactions, 2015, 43, 229-234.	3.4	20
117	Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Molecular Therapy, 2015, 23, 1759-1771.	8.2	73
118	Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Scientific Reports, 2015, 5, 12166.	3.3	82
119	Targeted next-generation sequencing to diagnose disorders of HDL cholesterol. Journal of Lipid Research, 2015, 56, 1993-2001.	4.2	28
120	Comment on Rickels et al. Loss-of-Function Mutations inABCA1and Enhanced Î²-Cell Secretory Capacity in Young Adults. Diabetes 2015;64:193â€“199. Diabetes, 2015, 64, e25-e26.	0.6	2
121	A new mutation for Huntington disease following maternal transmission of an intermediate allele. European Journal of Medical Genetics, 2015, 58, 28-30.	1.3	22
122	Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. Molecular Neurobiology, 2015, 52, 1850-1861.	4.0	31
123	Autophagy in Huntington disease and huntingtin in autophagy. Trends in Neurosciences, 2015, 38, 26-35.	8.6	277
124	Clinical, Biochemical, and Molecular Characterization of Novel Mutations in ABCA1 in Families with Tangier Disease. JIMD Reports, 2014, 18, 51-62.	1.5	19
125	p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Human Molecular Genetics, 2014, 23, 717-729.	2.9	42
126	HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 3032-3037.	7.1	85

#	Article	IF	Citations
127	Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics Journal, 2014, 14, 160-170.	2.0	29
128	Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of Huntingtin. Human Molecular Genetics, 2014, 23, 3166-3179.	2.9	56
129	Hepatic ABCA1 Expression Improves Â-Cell Function and Glucose Tolerance. Diabetes, 2014, 63, 4076-4082.	0.6	19
130	Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families. Clinical Genetics, 2014, 85, 433-440.	2.0	19
131	In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides. Molecular Therapy, 2014, 22, 2093-2106.	8.2	115
132	Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clinical Pharmacology and Therapeutics, 2014, 95, 253-253.	4.7	20
133	The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clinical Genetics, 2014, 86, 21-28.	2.0	68
134	Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics, 2014, 15, 1185-1195.	1.3	8
135	Bidirectional Control of Postsynaptic Density-95 (PSD-95) Clustering by Huntingtin. Journal of Biological Chemistry, 2014, 289, 3518-3528.	3.4	30
136	The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's disease. Human Molecular Genetics, 2014, 23, 4142-4160.	2.9	58
137	IGF-1 Intranasal Administration Rescues Huntington's Disease Phenotypes in YAC128 Mice. Molecular Neurobiology, 2014, 49, 1126-1142.	4.0	60
138	Evidenceâ€based genetic counselling implications for Huntington disease intermediate allele predictive test results. Clinical Genetics, 2014, 85, 303-311.	2.0	35
139	Personalized gene silencing therapeutics for Huntington disease. Clinical Genetics, 2014, 86, 29-36.	2.0	44
140	Codeine-related deaths: The role of pharmacogenetics and drug interactions. Forensic Science International, 2014, 239, 50-56.	2.2	41
141	Developmental Biology: Frontiers for Clinical Genetics. Clinical Genetics, 2014, 86, no.	2.0	2
142	High density lipoprotein metabolism in low density lipoprotein receptor-deficient mice. Journal of Lipid Research, 2014, 55, 1914-1924.	4.2	17
143	Pharmacogenomic diversity in Singaporean populations and Europeans. Pharmacogenomics Journal, 2014, 14, 555-563.	2.0	15
144	Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. Journal of Lipid Research, 2014, 55, 1693-1701.	4.2	24

#	Article	IF	Citations
145	ABCA1 in adipocytes regulates adipose tissue lipid content, glucose tolerance, and insulin sensitivity. Journal of Lipid Research, 2014, 55, 516-523.	4.2	76
146	Use of genetic technologies to compare medicines. Clinical Genetics, 2014, 86, 441-446.	2.0	0
147	Public Perceptions of Pharmacogenetics. Pediatrics, 2014, 133, e1258-e1267.	2.1	26
148	Response to â€œEvaluation of Pharmacogenetic Markers to Predict the Risk of Cisplatin-Induced Ototoxicityâ€• Clinical Pharmacology and Therapeutics, 2014, 96, 158-158.	4.7	2
149	Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis. Journal of Neuroimmunology, 2014, 274, 38-45.	2.3	15
150	Genetic Markers of Cisplatin-Induced Hearing Loss in Children. Clinical Pharmacology and Therapeutics, 2014, 96, 296-298.	4.7	7
151	VKORC1 and CYP2C9 genotypes are predictors of warfarinâ€related outcomes in children. Pediatric Blood and Cancer, 2014, 61, 1055-1062.	1.5	36
152	Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk. Movement Disorders, 2014, 29, 105-114.	3.9	125
153	Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic. PLoS ONE, 2014, 9, e83757.	2.5	35
154	Identification of Binding Sites in Huntingtin for the Huntingtin Interacting Proteins HIP14 and HIP14L. PLoS ONE, 2014, 9, e90669.	2.5	24
155	Striatal Synaptic Dysfunction and Hippocampal Plasticity Deficits in the Hu97/18 Mouse Model of Huntington Disease. PLoS ONE, 2014, 9, e94562.	2.5	35
156	Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients. PLoS ONE, 2014, 9, e107434.	2.5	92
157	Abstract W P205: Specific Deficiency of Brain ABCA1 Increases Inflammation and White Matter Damage and Worsens Functional Outcome After Stroke. Stroke, 2014, 45, .	2.0	0
158	â€œGrasping the Greyâ€: Patient Understanding and Interpretation of an Intermediate Allele Predictive Test Result for Huntington Disease. Journal of Genetic Counseling, 2013, 22, 200-217.	1.6	25
159	Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children. Clinical Pharmacology and Therapeutics, 2013, 94, 243-251.	4.7	109
160	Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nature Medicine, 2013, 19, 1030-1038.	30.7	108
161	Hunting human disease genes: lessons from the past, challenges for the future. Human Genetics, 2013, 132, 603-617.	3.8	31
162	HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children. Clinical Pharmacology and Therapeutics, 2013, 94, 142-149.	4.7	110

#	Article	IF	Citations
163	Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. European Journal of Human Genetics, 2013, 21, 1120-1127.	2.8	52
164	CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. Journal of Medical Genetics, 2013, 50, 696-703.	3.2	65
165	A systematic review and metaâ€analysis of clinical variables used in Huntington disease research. Movement Disorders, 2013, 28, 1987-1994.	3.9	8
166	Choosing an animal model for the study of Huntington's disease. Nature Reviews Neuroscience, 2013, 14, 708-721.	10.2	287
167	Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntingtonâ€™s disease motor onset. Neurogenetics, 2013, 14, 173-179.	1.4	10
168	High frequency of intermediate alleles on huntington diseaseâ€associated haplotypes in British Columbia's general population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 864-871.	1.7	44
169	Special new feature inClinical Genetics. Clinical Genetics, 2013, 83, 1-1.	2.0	0
170	Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease. Human Molecular Genetics, 2013, 22, 452-465.	2.9	59
171	Tracking Brain Palmitoylation Change: Predominance of Glial Change in a Mouse Model of Huntingtonâ€™s Disease. Chemistry and Biology, 2013, 20, 1421-1434.	6.0	81
172	ABCA1 influences neuroinflammation and neuronal death. Neurobiology of Disease, 2013, 54, 445-455.	4.4	71
173	Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Research, 2013, 41, 9634-9650.	14.5	138
174	Cancer Pharmacogenomics in Children: Research Initiatives and Progress to Date. Paediatric Drugs, 2013, 15, 71-81.	3.1	8
175	From Mutation Identification to Therapy: Discovery and Origins of the First Approved Gene Therapy in the Western World. Human Gene Therapy, 2013, 24, 472-478.	2.7	41
176	A fully humanized transgenic mouse model of Huntington disease. Human Molecular Genetics, 2013, 22, 18-34.	2.9	93
177	Developing a comprehensive, effective patient-friendly website to enhance decision making in predictive testing for Huntington disease. Genetics in Medicine, 2013, 15, 466-472.	2.4	8
178	When access is an issue: exploring barriers to predictive testing for Huntington disease in British Columbia, Canada. European Journal of Human Genetics, 2013, 21, 148-153.	2.8	20
179	Intrinsic cleavage of receptor-interacting protein kinase-1 by caspase-6. Cell Death and Differentiation, 2013, 20, 86-96.	11.2	36
180	The Salmonella Type III Effector SspH2 Specifically Exploits the NLR Co-chaperone Activity of SGT1 to Subvert Immunity. PLoS Pathogens, 2013, 9, e1003518.	4.7	80

#	Article	IF	Citations
181	The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans. Circulation: Cardiovascular Genetics, 2013, 6, 54-62.	5.1	53
182	Regulation of ABCA1 Protein Expression and Function in Hepatic and Pancreatic Islet Cells by miR-145. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2724-2732.	2.4	106
183	Putative Association of ABCB1 2677G>T/A With Oxycodone-Induced Central Nervous System Depression in Breastfeeding Mothers. Therapeutic Drug Monitoring, 2013, 35, 466-472.	2.0	17
184	De novo Huntington disease caused by 26â€“44 CAG repeat expansion on a low-risk haplotype. Neurology, 2013, 81, 1099-1100.	1.1	11
185	Memory and synaptic deficits in Hip14/DHHC17 knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20296-20301.	7.1	45
186	Providing predictive testing for Huntington disease via telehealth: results of a pilot study in British Columbia, Canada. Clinical Genetics, 2013, 84, 60-64.	2.0	29
187	Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracyclineâ€induced cardiotoxicity in children. Pediatric Blood and Cancer, 2013, 60, 1375-1381.	1.5	166
188	Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 217-228.	1.9	58
189	Life-Threatening Adverse Events Following Therapeutic Opioid Administration in Adults: Is Pharmacogenetic Analysis Useful?. Pain Research and Management, 2013, 18, 133-136.	1.8	17
190	A Clinical Tool for Reducing Central Nervous System Depression among Neonates Exposed to Codeine through Breast Milk. PLoS ONE, 2013, 8, e70073.	2.5	34
191	Pharmacogenomics of vincristineâ€induced neurotoxicity in pediatric cancer patients. FASEB Journal, 2013, 27, 666.3.	0.5	0
192	An investigation of morphineâ€toâ€codeine metabolic ratios in postmortem blood, drug interactions, and cytochrome P450 2D6 (CYP2D6) genotype. FASEB Journal, 2013, 27, 666.2.	0.5	0
193	Predicting Anthracyclineâ€induced Cardiotoxicity in Children â€“ Genomeâ€Wide Association Study. FASEB Journal, 2013, 27, 663.3.	0.5	0
194	Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Human Molecular Genetics, 2012, 21, 2219-2232.	2.9	122
195	Postpartum Maternal Codeine Therapy and the Risk of Adverse Neonatal Outcomes. Therapeutic Drug Monitoring, 2012, 34, 378-380.	2.0	11
196	Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Human Molecular Genetics, 2012, 21, 1954-1967.	2.9	67
197	Peripheral and cerebral metabolic features in an animal model of Huntington's disease. , 2012, , .		1
198	miR-33a Modulates ABCA1 Expression, Cholesterol Accumulation, and Insulin Secretion in Pancreatic Islets. Diabetes, 2012, 61, 653-658.	0.6	122

#	Article	IF	Citations
199	Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. Journal of Clinical Oncology, 2012, 30, 1422-1428.	1.6	341
200	Transgenic Mouse Model Expressing the Caspase 6 Fragment of Mutant Huntingtin. Journal of Neuroscience, 2012, 32, 183-193.	3.6	49
201	Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. Journal of Huntington's Disease, 2012, 1, 243-260.	1.9	7
202	Personalized Medicine: Temper Expectationsâ€"Response. Science, 2012, 337, 911-911.	12.6	2
203	Prediction of Codeine Toxicity in Infants and Their Mothers Using a Novel Combination of Maternal Genetic Markers. Clinical Pharmacology and Therapeutics, 2012, 91, 692-699.	4.7	69
204	Human Mendelian pain disorders: a key to discovery and validation of novel analgesics. Clinical Genetics, 2012, 82, 367-373.	2.0	34
205	CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology, 2012, 78, 690-695.	1.1	303
206	Polyglutamine diseases and the risk of cancer. Lancet Oncology, The, 2012, 13, 569-571.	10.7	1
207	Population stratification may bias analysis of PGC-1Î± as a modifier of age at Huntington disease motor onset. Human Genetics, 2012, 131, 1833-1840.	3.8	26
208	Putting proteins in their place: Palmitoylation in Huntington disease and other neuropsychiatric diseases. Progress in Neurobiology, 2012, 97, 220-238.	5.7	118
209	Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2012, 1821, 416-424.	2.4	50
210	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntingtonâ€™s disease. Biochemical and Biophysical Research Communications, 2012, 424, 404-408.	2.1	20
211	More Codeine Fatalities After Tonsillectomy in North American Children. Pediatrics, 2012, 129, e1343-e1347.	2.1	334
212	Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine, 2012, 18, 634-643.	6.7	116
213	NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2012, 48, 282-289.	4.4	47
214	Apnea and Oxygen Desaturations in Children Treated with Opioids after Adenotonsillectomy for Obstructive Sleep Apnea Syndrome. Paediatric Drugs, 2012, 14, 411-415.	3.1	29
215	Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics Journal, 2012, 12, 233-237.	2.0	158
216	Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. Journal of Huntington's Disease, 2012, 1, 221-241.	1.9	13

#	Article	IF	Citations
217	Economic impact of a genetic test for cisplatin-induced ototoxicity. Pharmacogenomics Journal, 2012, 12, 205-213.	2.0	21
218	Loss of Both ABCA1 and ABCG1 Results in Increased Disturbances in Islet Sterol Homeostasis, Inflammation, and Impaired Î²-Cell Function. Diabetes, 2012, 61, 659-664.	0.6	107
219	Whole-Genome Sequencing: The New Standard of Care?. Science, 2012, 336, 1112-1113.	12.6	63
220	Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene Region. American Journal of Human Genetics, 2012, 90, 434-444.	6.2	60
221	Adoption and the communication of genetic risk: experiences in Huntington disease. Clinical Genetics, 2012, 81, 64-69.	2.0	7
222	What monozygotic twins discordant for phenotype illustrate about mechanisms influencing genetic forms of neurodegeneration. Clinical Genetics, 2012, 81, 325-333.	2.0	36
223	Central Nervous System Depression of Neonates Breastfed by Mothers Receiving Oxycodone for Postpartum Analgesia. Journal of Pediatrics, 2012, 160, 33-37.e2.	1.8	108
224	Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2012, 45, 438-449.	4.4	105
225	Treatment of Nav1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain, 2012, 153, 80-85.	4.2	116
226	Beyond the patient: The broader impact of genetic discrimination among individuals at risk of Huntington disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 217-226.	1.7	37
227	Low Levels of Human HIP14 Are Sufficient to Rescue Neuropathological, Behavioural, and Enzymatic Defects Due to Loss of Murine HIP14 in Hip14â^'/â^' Mice. PLoS ONE, 2012, 7, e36315.	2.5	10
228	Segregation of LIPG, CETP, and GALNT2 Mutations in Caucasian Families with Extremely High HDL Cholesterol. PLoS ONE, 2012, 7, e37437.	2.5	28
229	Apnea and Oxygen Desaturations in Children Treated with Opioids after Adenotonsillectomy for Obstructive Sleep Apnea Syndrome. Paediatric Drugs, 2012, 14, 411-415.	3.1	12
230	Diagnostic Testing for Vaccinomics: Is the Regulatory Approval Framework Adequate? A Comparison of Canada, the United States, and Europe. OMICS A Journal of Integrative Biology, 2011, 15, 597-605.	2.0	3
231	Small Changes, Big Impact. Neuroscientist, 2011, 17, 475-492.	3.5	159
232	Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nature Reviews Drug Discovery, 2011, 10, 853-867.	46.4	70
233	Altered palmitoylation and neuropathological deficits in mice lacking HIP14. Human Molecular Genetics, 2011, 20, 3899-3909.	2.9	103
234	The Dynamics of Macrophage Infiltration into the Arterial Wall during Atherosclerotic Lesion Development in Low-Density Lipoprotein Receptor Knockout Mice. American Journal of Pathology, 2011, 178, 413-422.	3.8	24

#	Article	IF	Citations
235	Islet Cholesterol Accumulation Due to Loss of ABCA1 Leads to Impaired Exocytosis of Insulin Granules. Diabetes, 2011, 60, 3186-3196.	0.6	97
236	Caspase-6 and neurodegeneration. Trends in Neurosciences, 2011, 34, 646-656.	8.6	114
237	Lessons from predictive testing for Huntington disease: 25 years on. Journal of Medical Genetics, 2011, 48, 649-650.	3.2	17
238	Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin. Molecular Therapy, 2011, 19, 2178-2185.	8.2	246
239	Cholesterol metabolism in Huntington disease. Nature Reviews Neurology, 2011, 7, 561-572.	10.1	122
240	Amelioration of Hypertriglyceridemia with Hypo-Alpha-Cholesterolemia in LPL Deficient Mice by Hematopoietic Cell-Derived LPL. PLoS ONE, 2011, 6, e25620.	2.5	4
241	CYP2D6 Polymorphisms and Codeine Analgesia in Postpartum Pain Management: A Pilot Study. Therapeutic Drug Monitoring, 2011, 33, 425-432.	2.0	45
242	Pharmacogenomics of Cardiovascular Drugs and Adverse Effects in Pediatrics. Journal of Cardiovascular Pharmacology, 2011, 58, 228-239.	1.9	22
243	Novel mutations in scavenger receptor BI associated with high HDL cholesterol in humans. Clinical Genetics, 2011, 79, 575-581.	2.0	70
244	Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nature Medicine, 2011, 17, 377-382.	30.7	467
245	HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. European Journal of Human Genetics, 2011, 19, 561-566.	2.8	140
246	Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiology of Disease, 2011, 41, 249-260.	4.4	92
247	Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington disease. Neurobiology of Disease, 2011, 43, 257-265.	4.4	65
248	Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Molecular Neurodegeneration, 2011, 6, 59.	10.8	30
249	Factors associated with experiences of genetic discrimination among individuals at risk for huntington disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 19-27.	1.7	14
250	A grand challenge: Providing benefits of clinical genetics to those in need. Genetics in Medicine, 2011, 13, 197-200.	2.4	54
251	Wild-type HTT modulates the enzymatic activity of the neuronal palmitoyl transferase HIP14. Human Molecular Genetics, 2011, 20, 3356-3365.	2.9	71
252	A Quantitative Method for the Specific Assessment of Caspase-6 Activity in Cell Culture. PLoS ONE, 2011, 6, e27680.	2.5	27

#	Article	IF	Citations
253	Unstable familial transmissions of Huntington disease alleles with 27â€“35 CAG repeats (intermediate) Tj ETQq1 1 0.784314 rgBT /Over	1.7	37
254	HDL and LDL cholesterol significantly influence Î²-cell function in type 2 diabetes mellitus. Current Opinion in Lipidology, 2010, 21, 178-185.	2.7	120
255	Cholesterol efflux via ATP-binding cassette transporter A1 (ABCA1) and cholesterol uptake via the LDL receptor influences cholesterol-induced impairment of beta cell function in mice. Diabetologia, 2010, 53, 1110-1119.	6.3	108
256	Cholesterol toxicity in pancreatic islets from LDL receptor-deficient mice. Reply to: de Souza JC, de Oliveira CAM, Carneiro EM et al. [letter]. Diabetologia, 2010, 53, 2463-2464.	6.3	1
257	Cholesterol in Î²-cell Dysfunction: The Emerging Connection Between HDL Cholesterol and Type 2 Diabetes. Current Diabetes Reports, 2010, 10, 55-60.	4.2	54
258	Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiology of Disease, 2010, 40, 207-215.	4.4	90
259	Adenosine-Triphosphate-Binding Cassette Transporter-1 Trafficking and Function. Trends in Cardiovascular Medicine, 2010, 20, 41-49.	4.9	37
260	CAGâ€repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 397-408.	1.7	289
261	Perception, experience, and response to genetic discrimination in Huntington disease: The international RESPONDâ€HD study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1081-1093.	1.7	42
262	In their own words: Reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPONDâ€HD study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1150-1159.	1.7	33
263	Communicating Pharmacogenetic Research Results to Breastfeeding Mothers Taking Codeine: A Pilot Study of Perceptions and Benefits. Clinical Pharmacology and Therapeutics, 2010, 88, 792-795.	4.7	23
264	BDNF Overexpression in the Forebrain Rescues Huntington's Disease Phenotypes in YAC128 Mice. Journal of Neuroscience, 2010, 30, 14708-14718.	3.6	223
265	Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Human Molecular Genetics, 2010, 19, 1438-1452.	2.9	91
266	Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Human Molecular Genetics, 2010, 19, 1528-1538.	2.9	100
267	Glucose intolerance and decreased early insulin response in mice with severe hypertriglyceridemia. Experimental Biology and Medicine, 2010, 235, 40-46.	2.4	9
268	Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia. Journal of Lipid Research, 2010, 51, 1535-1545.	4.2	103
269	Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology, 2010, 75, 1702-1710.	1.1	107
270	Targeted Deletion of Hepatocyte ABCA1 Leads to Very Low Density Lipoprotein Triglyceride Overproduction and Low Density Lipoprotein Hypercatabolism. Journal of Biological Chemistry, 2010, 285, 12197-12209.	3.4	81

#	Article	IF	Citations
271	The Canadian Pharmacogenomics Network for Drug Safety: A Model for Safety Pharmacology. Thyroid, 2010, 20, 681-687.	4.5	67
272	Fatal Hydrocodone Overdose in a Child: Pharmacogenetics and Drug Interactions. Pediatrics, 2010, 126, e986-e989.	2.1	84
273	A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Human Molecular Genetics, 2010, 19, 2877-2885.	2.9	133
274	Phosphorylation of Huntingtin at Ser⁴²¹in YAC128 Neurons Is Associated with Protection of YAC128 Neurons from NMDA-Mediated Excitotoxicity and Is Modulated by PP1 and PP2A. Journal of Neuroscience, 2010, 30, 14318-14329.	3.6	81
275	Cleavage at the 586 Amino Acid Caspase-6 Site in Mutant huntingtin Influences Caspase-6 ActivationIn Vivo. Journal of Neuroscience, 2010, 30, 15019-15029.	3.6	94
276	Carriers of Loss-of-Function Mutations in ABCA1 Display Pancreatic Â-Cell Dysfunction. Diabetes Care, 2010, 33, 869-874.	8.6	114
277	Cholesterol Defect Is Marked across Multiple Rodent Models of Huntington's Disease and Is Manifest in Astrocytes. Journal of Neuroscience, 2010, 30, 10844-10850.	3.6	136
278	Pharmacogenomics and active surveillance for serious adverse drug reactions in children. Pharmacogenomics, 2010, 11, 1269-1285.	1.3	19
279	Cocaine adulterant linked to neutropenia. Cmaj, 2010, 182, 57-59.	2.0	25
280	The metabolic phenotype of SCD1-deficient mice is independent of melanin-concentrating hormone. Peptides, 2010, 31, 123-129.	2.4	2
281	Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice. Neuron, 2010, 65, 178-190.	8.1	448
282	Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice. Neuron, 2010, 65, 436.	8.1	2
283	Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis, 2010, 211, 231-236.	0.8	64
284	Interaction of Postsynaptic Density Protein-95 with NMDA Receptors Influences Excitotoxicity in the Yeast Artificial Chromosome Mouse Model of Huntington's Disease. Journal of Neuroscience, 2009, 29, 10928-10938.	3.6	85
285	Tissue-Specific Roles of ABCA1 Influence Susceptibility to Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 548-554.	2.4	98
286	Palmitoylation of ATP-Binding Cassette Transporter A1 Is Essential for Its Trafficking and Function. Circulation Research, 2009, 105, 138-147.	4.5	70
287	Despite Antiatherogenic Metabolic Characteristics, SCD1-Deficient Mice Have Increased Inflammation and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 341-347.	2.4	95
288	Specific Loss of Brain ABCA1 Increases Brain Cholesterol Uptake and Influences Neuronal Structure and Function. Journal of Neuroscience, 2009, 29, 3579-3589.	3.6	116

#	Article	IF	Citations
289	Presynaptic Defects Underlying Impaired Learning and Memory Function in Lipoprotein Lipase-Deficient Mice. Journal of Neuroscience, 2009, 29, 4681-4685.	3.6	65
290	Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells. Journal of Biological Chemistry, 2009, 284, 10855-10867.	3.4	124
291	Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease. Journal of Neuroscience, 2009, 29, 2193-2204.	3.6	123
292	Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease. Journal of Neuroscience, 2009, 29, 2414-2427.	3.6	160
293	Perceptions of genetic discrimination among people at risk for Huntington's disease: a cross sectional survey. BMJ: British Medical Journal, 2009, 338, b2175-b2175.	2.3	98
294	Neuronal palmitoyl acyl transferases exhibit distinct substrate specificity. FASEB Journal, 2009, 23, 2605-2615.	0.5	138
295	Application of principal component analysis to pharmacogenomic studies in Canada. Pharmacogenomics Journal, 2009, 9, 362-372.	2.0	23
296	Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9016-9020.	7.1	53
297	Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipase-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells. Gut, 2009, 58, 422-430.	12.1	61
298	IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. Journal of Cell Biology, 2009, 187, 1083-1099.	5.2	343
299	Plasma apolipoprotein AV levels in mice are positively associated with plasma triglyceride levels. Journal of Lipid Research, 2009, 50, 880-884.	4.2	13
300	Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. Pharmacoepidemiology and Drug Safety, 2009, 18, 713-721.	1.9	70
301	Pharmacogenetics of Neonatal Opioid Toxicity Following Maternal Use of Codeine During Breastfeeding: A Caseâ€“Control Study. Clinical Pharmacology and Therapeutics, 2009, 85, 31-35.	4.7	284
302	Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature Genetics, 2009, 41, 1345-1349.	21.4	287
303	Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Medicine, 2009, 15, 1407-1413.	30.7	381
304	Tetrabenazine. Nature Reviews Drug Discovery, 2009, 8, 17-18.	46.4	47
305	The role of free fatty acids, pancreatic lipase and Ca²⁺ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipaseâ€deficient mice. Acta Physiologica, 2009, 195, 13-28.	3.8	73
306	CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing Haplogroup. American Journal of Human Genetics, 2009, 84, 351-366.	6.2	204

#	Article	IF	Citations
307	Response to Falush: A Role for cis-Element Polymorphisms in HD. American Journal of Human Genetics, 2009, 85, 942-945.	6.2	5
308	Acute hypertriglyceridemic pancreatitis during pregnancy due to homozygous lipoprotein lipase gene mutation. Clinica Chimica Acta, 2009, 400, 137-138.	1.1	7
309	Absence of stearoyl-CoA desaturase-1 does not promote DSS-induced acute colitis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 1166-1172.	2.4	12
310	Enhanced atherothrombotic formation after oxidative injury by FeCl3 to the common carotid artery in severe combined hyperlipidemic mice. Biochemical and Biophysical Research Communications, 2009, 385, 563-569.	2.1	7
311	Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Molecular and Cellular Neurosciences, 2009, 40, 121-127.	2.2	86
312	Mouse models of Huntington disease: variations on a theme. DMM Disease Models and Mechanisms, 2009, 2, 123-129.	2.4	91
313	Subtype-Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin. Journal of Neurochemistry, 2008, 72, 1890-1898.	3.9	166
314	Re: Autopsyâ€proven Huntington's disease with 29 trinucleotide repeats. Movement Disorders, 2008, 23, 1794-1795.	3.9	20
315	Perceptions of discrimination among persons who have undergone predictive testing for Huntington's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 320-325.	1.7	42
316	Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. European Journal of Human Genetics, 2008, 16, 279-289.	2.8	57
317	DNA analysis of distinct populations suggests multiple origins for the mutation causing Huntington disease. Clinical Genetics, 2008, 43, 286-294.	2.0	24
318	Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Neurobiology of Disease, 2008, 31, 80-88.	4.4	110
319	Automated deformation analysis in the YAC128 Huntington disease mouse model. NeuroImage, 2008, 39, 32-39.	4.2	150
320	Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. NeuroImage, 2008, 41, 243-251.	4.2	115
321	<emph type="ital">ABCA1</emph> Gene Mutations, HDL Cholesterol Levels, and Risk of Ischemic Heart Disease. JAMA - Journal of the American Medical Association, 2008, 300, 1997.	7.4	15
322	Spontaneous Atherosclerosis in Aged Lipoprotein Lipaseâ€"Deficient Mice With Severe Hypertriglyceridemia on a Normal Chow Diet. Circulation Research, 2008, 102, 250-256.	4.5	88
323	Detection of Huntington's disease decades before diagnosis: the Predict-HD study. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 874-880.	1.9	696
324	Intramuscular Administration of AAV1-Lipoprotein Lipase ^{S447X} Lowers Triglycerides in Lipoprotein Lipaseâ€"Deficient Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2303-2304.	2.4	201

#	Article	IF	Citations
325	Response to the Letter by Ebara et al. Circulation Research, 2008, 102, .	4.5	1
326	Polyglutamine-Modulated Striatal Calpain Activity in YAC Transgenic Huntington Disease Mouse Model: Impact on NMDA Receptor Function and Toxicity. Journal of Neuroscience, 2008, 28, 12725-12735.	3.6	68
327	Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice. Journal of Lipid Research, 2008, 49, 217-229.	4.2	59
328	Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus. Human Molecular Genetics, 2008, 17, 2390-2404.	2.9	112
329	Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Human Molecular Genetics, 2008, 17, 2738-2751.	2.9	139
330	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. Journal of Experimental Medicine, 2008, 205, 1869-1877.	8.5	559
331	Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain, 2008, 132, 919-932.	7.6	135
332	Cholesterol in islet dysfunction and type 2 diabetes. Journal of Clinical Investigation, 2008, 118, 403-408.	8.2	125
333	Altered NMDA Receptor Trafficking in a Yeast Artificial Chromosome Transgenic Mouse Model of Huntington's Disease. Journal of Neuroscience, 2007, 27, 3768-3779.	3.6	112
334	NMDA Receptor Function and NMDA Receptor-Dependent Phosphorylation of Huntingtin Is Altered by the Endocytic Protein HIP1. Journal of Neuroscience, 2007, 27, 2298-2308.	3.6	41
335	Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain, 2007, 130, 1732-1744.	7.6	181
336	N-Terminal Proteolysis of Full-Length Mutant Huntingtin in an Inducible PC12 Cell Model of Huntingtonâ€™s Disease. Cell Cycle, 2007, 6, 2970-2981.	2.6	59
337	Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Human Molecular Genetics, 2007, 16, 2187-2198.	2.9	106
338	Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-Î² peptide levels in vivo. Journal of Lipid Research, 2007, 48, 914-923.	4.2	13
339	Huntingtin-Interacting Protein 1 Influences Worm and Mouse Presynaptic Function and ProtectsCaenorhabditis elegansNeurons against Mutant Polyglutamine Toxicity. Journal of Neuroscience, 2007, 27, 11056-11064.	3.6	61
340	Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics, 2007, 16, 1845-1861.	2.9	304
341	Mitochondrial Sensitivity and Altered Calcium Handling Underlie Enhanced NMDA-Induced Apoptosis in YAC128 Model of Huntington's Disease. Journal of Neuroscience, 2007, 27, 13614-13623.	3.6	111
342	Expression of LPL in Endothelial-Intact Artery Results in Lipid Deposition and Vascular Cell Adhesion Molecule-1 Upregulation in Both LPL and ApoE-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 197-203.	2.4	28

#	Article	IF	Citations
343	Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntingtonâ€™s disease. Neuroscience, 2007, 147, 354-372.	2.3	48
344	Selective degeneration in YAC mouse models of Huntington disease. Brain Research Bulletin, 2007, 72, 124-131.	3.0	53
345	Pharmacogenomics and its implications for autoimmune disease. Journal of Autoimmunity, 2007, 28, 122-128.	6.5	27
346	Chapter 15 Juvenile amyotrophic lateral sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 82, 301-312.	1.8	42
347	When good drugs go bad. Nature, 2007, 446, 975-977.	27.8	246
348	Î²-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nature Medicine, 2007, 13, 340-347.	30.7	366
349	Managing genetic discrimination: Strategies used by individuals found to have the Huntington disease mutation. Clinical Genetics, 2007, 71, 220-231.	2.0	33
350	Lossâ€ofâ€function mutations in the Na_v1.7 gene underlie congenital indifference to pain in multiple human populations. Clinical Genetics, 2007, 71, 311-319.	2.0	404
351	Protective up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA receptors. Journal of Neurochemistry, 2007, 104, 071106220454003-???.	3.9	21
352	CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics, 2007, 8, 126.	2.8	78
353	Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiology of Disease, 2007, 26, 189-200.	4.4	97
354	Testicular degeneration in Huntington disease. Neurobiology of Disease, 2007, 26, 512-520.	4.4	90
355	Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia, 2007, 45, 1767-1776.	1.6	122
356	Genotypic Approaches to Therapy in Children: A National Active Surveillance Network (GATC) to Study the Pharmacogenomics of Severe Adverse Drug Reactions in Children. Annals of the New York Academy of Sciences, 2007, 1110, 177-192.	3.8	28
357	Mycophenolate Mofetil and Atherosclerosis: Results of Animal and Human Studies. Annals of the New York Academy of Sciences, 2007, 1110, 209-221.	3.8	23
358	Structural abnormalities in spermatids together with reduced sperm counts and motility underlie the reproductive defect in HIP1âˆ’/âˆ’ mice. Molecular Reproduction and Development, 2007, 74, 341-359.	2.0	25
359	Tu-W23:4 Hepatic ABCA1 is a key molecule in HDL cholesteryl ester metabolism in mice. Atherosclerosis Supplements, 2006, 7, 166-167.	1.2	0
360	Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin. Cell, 2006, 125, 1179-1191.	28.9	600

#	Article	IF	Citations
361	Hemorheological abnormalities in lipoprotein lipase deficient mice with severe hypertriglyceridemia. Biochemical and Biophysical Research Communications, 2006, 341, 1066-1071.	2.1	22
362	Hippi is essential for node cilia assembly and Sonic hedgehog signaling. Developmental Biology, 2006, 300, 523-533.	2.0	86
363	Molecular Pathogenesis of Huntington's Disease: The Role of Excitotoxicity. , 2006, , 251-260.		1
364	Genome-wide significance for a modifier of age at neurological onset in Huntington's Disease at 6q23-24: the HD MAPS study. BMC Medical Genetics, 2006, 7, 71.	2.1	72
365	Cerebrospinal fluid levels of orexinâ€A are not a clinically useful biomarker for Huntington disease. Clinical Genetics, 2006, 70, 78-79.	2.0	31
366	The genotype-phenotype correlation of hereditary multiple exostoses. Clinical Genetics, 2006, 70, 122-130.	2.0	68
367	Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clinical Genetics, 2006, 70, 283-294.	2.0	110
368	Palmitoylation of huntingtin by HIP14is essential for its trafficking and function. Nature Neuroscience, 2006, 9, 824-831.	14.8	266
369	Huntingtin inhibits caspase-3 activation. EMBO Journal, 2006, 25, 5896-5906.	7.8	88
370	Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry, 2006, 96, 1121-1129.	3.9	145
371	To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends in Genetics, 2006, 22, 408-411.	6.7	32
372	FASA-57 cDNA shares no homology with coding sequence of HD gene. Journal of Reproductive Immunology, 2006, 69, 9-10.	1.9	0
373	Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiology of Disease, 2006, 21, 392-403.	4.4	108
374	Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiology of Disease, 2006, 21, 444-455.	4.4	77
375	Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease, 2006, 23, 190-197.	4.4	137
376	Elevated plasma triglyceride levels precede amyloid deposition in Alzheimerâ€™s disease mouse models with abundant Aî² in plasma. Neurobiology of Disease, 2006, 24, 114-127.	4.4	112
377	Brain-derived neurotrophic factor does not influence age at neurologic onset of Huntingtonâ€™s disease. Neurobiology of Disease, 2006, 24, 280-285.	4.4	31
378	Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neuroscience, 2006, 7, 80.	1.9	47

#	Article	IF	Citations
379	Preparing for Preventive Clinical Trials. Archives of Neurology, 2006, 63, 883.	4.5	292
380	Mycophenolate mofetil (MMF): Firing at the atherosclerotic plaque from different angles?. Cardiovascular Research, 2006, 69, 341-347.	3.8	45
381	Body weight is modulated by levels of full-length Huntingtin. Human Molecular Genetics, 2006, 15, 1513-1523.	2.9	101
382	Lipoprotein Lipase S447X. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1236-1245.	2.4	140
383	Mycophenolate mofetil as an immunomodulatory silver bullet in atherogenesis?. Lupus, 2006, 15, 11-17.	1.6	2
384	Mycophenolate mofetil and animal models. Lupus, 2006, 15, 27-34.	1.6	0
385	Macrophage ATP-Binding Cassette Transporter A1 Overexpression Inhibits Atherosclerotic Lesion Progression in Low-Density Lipoprotein Receptor Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 929-934.	2.4	163
386	Specific Mutations in ABCA1 Have Discrete Effects on ABCA1 Function and Lipid Phenotypes Both In Vivo and In Vitro. Circulation Research, 2006, 99, 389-397.	4.5	92
387	Tissue-Specific Induction of Intestinal ABCA1 Expression With a Liver X Receptor Agonist Raises Plasma HDL Cholesterol Levels. Circulation Research, 2006, 99, 672-674.	4.5	103
388	Mutant Huntingtin: Nuclear translocation and cytotoxicity mediated by GAPDH. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3405-3409.	7.1	112
389	Hepatic ATP-Binding Cassette Transporter A1 Is a Key Molecule in High-Density Lipoprotein Cholesteryl Ester Metabolism in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1821-1827.	2.4	33
390	Both Hepatic and Extrahepatic ABCA1 Have Discrete and Essential Functions in the Maintenance of Plasma High-Density Lipoprotein Cholesterol Levels In Vivo. Circulation, 2006, 114, 1301-1309.	1.6	80
391	Mitochondrial-Dependent Ca2+ Handling in Huntington's Disease Striatal Cells: Effect of Histone Deacetylase Inhibitors. Journal of Neuroscience, 2006, 26, 11174-11186.	3.6	124
392	Als2 -deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9595-9600.	7.1	128
393	Variations on a Gene: Rare and Common Variants inABCA1and Their Impact on HDL Cholesterol Levels and Atherosclerosis. Annual Review of Nutrition, 2006, 26, 105-129.	10.1	139
394	Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease?. Nature Clinical Practice Neurology, 2006, 2, 536-537.	2.5	4
395	Correction of Feline Lipoprotein Lipase Deficiency with Adeno-Associated Virus Serotype 1-Mediated Gene Transfer of the Lipoprotein Lipase S447X Beneficial Mutation. Human Gene Therapy, 2006, 17, 487-499.	2.7	74
396	Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. Journal of Clinical Investigation, 2006, 116, 1052-1062.	8.2	447

#	Article	IF	Citations
397	Correction of Feline Lipoprotein Lipase Deficiency with Adeno-Associated Virus Serotype 1-Mediated Gene Transfer of the Lipoprotein Lipase S447X Beneficial Mutation. Human Gene Therapy, 2006, .	2.7	0
398	Cardiovascular disease in systemic lupus erythematosus: has the time for action come?. Current Opinion in Lipidology, 2005, 16, 501-506.	2.7	7
399	Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. Journal of Neurochemistry, 2005, 94, 1087-1101.	3.9	52
400	Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry, 2005, 95, 210-220.	3.9	96
401	Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. Journal of Neurochemistry, 2005, 95, 553-562.	3.9	74
402	Introduction to Social and Behavioural Research in Genetics. Clinical Genetics, 2005, 67, 480-480.	2.0	0
403	Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Human Molecular Genetics, 2005, 14, 1569-1577.	2.9	126
404	Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial. Neurology, 2005, 65, 286-292.	1.1	143
405	Huntingtin Associates with Acidic Phospholipids at the Plasma Membrane. Journal of Biological Chemistry, 2005, 280, 36464-36473.	3.4	133
406	Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Human Molecular Genetics, 2005, 14, 3823-3835.	2.9	152
407	Complete Rescue of Lipoprotein Lipaseâ€"Deficient Mice by Somatic Gene Transfer of the Naturally Occurring LPL S447X Beneficial Mutation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2143-2150.	2.4	60
408	Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Human Molecular Genetics, 2005, 14, 1379-1392.	2.9	149
409	Alternate transcripts expressed in response to diet reflect tissue-specific regulation of ABCA1. Journal of Lipid Research, 2005, 46, 2061-2071.	4.2	21
410	Complete functional rescue of the ABCA1â^'/â^' mouse by human BAC transgenesis. Journal of Lipid Research, 2005, 46, 1113-1123.	4.2	11
411	Huntingtin Interacting Protein 1 (HIP1) Regulates Clathrin Assembly through Direct Binding to the Regulatory Region of the Clathrin Light Chain. Journal of Biological Chemistry, 2005, 280, 6101-6108.	3.4	101
412	The Absence of ABCA1 Decreases Soluble ApoE Levels but Does Not Diminish Amyloid Deposition in Two Murine Models of Alzheimer Disease. Journal of Biological Chemistry, 2005, 280, 43243-43256.	3.4	203
413	Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11402-11407.	7.1	247
414	Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2602-2607.	7.1	336

#	Article	IF	Citations
415	W10-IS-001 Role of ABCA1 and SR-BI in cholesterol transport and atherosclerosis. Atherosclerosis Supplements, 2005, 6, 46.	1.2	0
416	Gene Therapy for Lipoprotein Lipase Deficiency: Working Toward Clinical Application. Human Gene Therapy, 2005, 16, 1276-1286.	2.7	55
417	Cross-species characterization of the ALS2 gene and analysis of its pattern of expression in development and adulthood. Neurobiology of Disease, 2005, 18, 243-257.	4.4	25
418	Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology, 2005, 196, 266-272.	4.1	60
419	Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease. Journal of Neuroscience, 2005, 25, 4169-4180.	3.6	282
420	Experimental models of Huntington's disease. Drug Discovery Today: Disease Models, 2005, 2, 291-297.	1.2	4
421	Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. Journal of Clinical Investigation, 2005, 115, 1333-1342.	8.2	407
422	Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. Journal of Clinical Investigation, 2005, 115, 1333-1342.	8.2	225
423	Accurate Prediction of the Functional Significance of Single Nucleotide Polymorphisms and Mutations in the ABCA1 Gene. PLoS Genetics, 2005, 1, e83.	3.5	115
424	Gene Therapy for Lipoprotein Lipase Deficiency: Working Toward Clinical Application. Human Gene Therapy, 2005, .	2.7	1
425	Psychosocial effects of predictive testing for Huntington's disease. Advances in Neurology, 2005, 96, 226-39.	0.8	11
426	Enhanced Striatal NR2B-Containing N-Methyl-d-Aspartate Receptor-Mediated Synaptic Currents in a Mouse Model of Huntington Disease. Journal of Neurophysiology, 2004, 92, 2738-2746.	1.8	107
427	Deficiency of ABCA1 Impairs Apolipoprotein E Metabolism in Brain. Journal of Biological Chemistry, 2004, 279, 41197-41207.	3.4	321
428	Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro. Molecular and Cellular Biology, 2004, 24, 8195-8209.	2.3	454
429	The ATP-binding cassette transporter 1 mediates lipid efflux from Sertoli cells and influences male fertility. Journal of Lipid Research, 2004, 45, 1040-1050.	4.2	86
430	Inhibition of Calpain Cleavage of Huntingtin Reduces Toxicity. Journal of Biological Chemistry, 2004, 279, 20211-20220.	3.4	242
431	Huntingtin Bodies Sequester Vesicle-Associated Proteins by a Polyproline-Dependent Interaction. Journal of Neuroscience, 2004, 24, 269-281.	3.6	157
432	A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics, 2004, 65, 267-277.	2.0	738

#	Article	IF	Citations
433	HAP1 facilitates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca2+ release in primary culture of striatal medium spiny neurons. European Journal of Neuroscience, 2004, 20, 1779-1787.	2.6	57
434	A homozygous HAMP mutation in a multiply consanguineous family with pseudo-dominant juvenile hemochromatosis. Clinical Genetics, 2004, 65, 378-383.	2.0	51
435	Mutations in HFE2 cause iron overload in chromosome 1qâ€“linked juvenile hemochromatosis. Nature Genetics, 2004, 36, 77-82.	21.4	900
436	Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death and Differentiation, 2004, 11, 424-438.	11.2	193
437	Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature, 2004, 429, 75-79.	27.8	395
438	Genetic testing and Huntington's disease: issues of employment. Lancet Neurology, The, 2004, 3, 249-252.	10.2	25
439	Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: A marker of cardiac dilatation. Molecular and Cellular Biochemistry, 2004, 264, 183-191.	3.1	23
440	Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics, 2004, 5, 109-114.	1.4	67
441	HDL deficiency and atherosclerosis: lessons from Tangier disease. Journal of Internal Medicine, 2004, 255, 299-301.	6.0	26
442	A case of tangier disease with a novel mutation in the c-terminal region of ATP-binding cassette transporter A1. American Journal of Medical Genetics Part A, 2004, 130A, 398-401.	2.4	7
443	Huntington's disease-like 2 (HDL2) in North America and Japan. Annals of Neurology, 2004, 56, 670-674.	5.3	105
444	Long-Term Correction of Murine Lipoprotein Lipase Deficiency with AAV1-Mediated Gene Transfer of the Naturally Occurring LPLS447XBeneficial Mutation. Human Gene Therapy, 2004, 15, 906-919.	2.7	67
445	A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. Journal of the American College of Cardiology, 2004, 44, 1429-1435.	2.8	124
446	Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. Experimental Neurology, 2004, 185, 26-35.	4.1	54
447	Deranged neuronal calcium signaling and Huntington disease. Biochemical and Biophysical Research Communications, 2004, 322, 1310-1317.	2.1	236
448	Huntingtin-Interacting Protein HIP14 Is a Palmitoyl Transferase Involved in Palmitoylation and Trafficking of Multiple Neuronal Proteins. Neuron, 2004, 44, 977-986.	8.1	271
449	Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Molecular and Cellular Neurosciences, 2004, 25, 469-479.	2.2	151
450	Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics, 2004, 74, 1064-1073.	6.2	133

#	Article	IF	Citations
451	O1-03-07 ABCA1 modulates APOE levels in brain and plasma. Neurobiology of Aging, 2004, 25, S15-S16.	3.1	1
452	Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking. EMBO Journal, 2003, 22, 3254-3266.	7.8	102
453	Predictive testing for Huntington's disease: a universal model?. Lancet Neurology, The, 2003, 2, 141-142.	10.2	31
454	Huntingtin proteolysis in Huntington disease. Clinical Neuroscience Research, 2003, 3, 129-139.	0.8	9
455	Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease. , 2003, 119A, 279-282.		146
456	CAG repeat polymorphisms in KCNN3 (HSKCa3) and PPP2R2B show no association or linkage to schizophrenia. , 2003, 116B, 45-50.		10
457	An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Annals of Neurology, 2003, 53, 144-145.	5.3	97
458	Predictive, preâ€natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clinical Genetics, 2003, 63, 462-475.	2.0	134
459	The first nonsense mutation in alsin results in a homogeneous phenotype of infantileâ€onset ascending spastic paralysis with bulbar involvement in two siblings. Clinical Genetics, 2003, 64, 210-215.	2.0	83
460	Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clinical Genetics, 2003, 64, 300-309.	2.0	107
461	Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene. Clinical Genetics, 2003, 64, 524-525.	2.0	11
462	Depletion of wild-type huntingtin in mouse models of neurologic diseases. Journal of Neurochemistry, 2003, 87, 101-106.	3.9	97
463	Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genetics, 2003, 35, 76-83.	21.4	807
464	Clarity is essential when using Nucleotide number systems. Atherosclerosis, 2003, 170, 349.	0.8	0
465	Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiology of Aging, 2003, 24, 1113-1121.	3.1	97
466	Caudate volume as an outcome measure in clinical trials for Huntingtonâ€™s disease: a pilot study. Brain Research Bulletin, 2003, 62, 137-141.	3.0	42
467	Heterozygosity for ABCA1 gene mutations: effects on enzymes, apolipoproteins and lipoprotein particle size. Atherosclerosis, 2003, 171, 311-319.	0.8	19
468	Skewed X-Chromosome Inactivation Is Associated with Trisomy in Women Ascertained on the Basis of Recurrent Spontaneous Abortion or Chromosomally Abnormal Pregnancies. American Journal of Human Genetics, 2003, 72, 399-407.	6.2	75

#	Article	IF	Citations
469	A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS Study. American Journal of Human Genetics, 2003, 73, 682-687.	6.2	148
470	Allelic variation in the promoter region of the LDL receptor gene: analysis of an African-specific variant in the FP2 cis-acting regulatory element. Molecular and Cellular Probes, 2003, 17, 175-181.	2.1	2
471	Huntingtin and Huntingtin-Associated Protein 1 Influence Neuronal Calcium Signaling Mediated by Inositol-(1,4,5) Triphosphate Receptor Type 1. Neuron, 2003, 39, 227-239.	8.1	442
472	Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain, 2003, 126, 946-955.	7.6	173
473	Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein. Circulation, 2003, 107, 2944-2948.	1.6	283
474	ABCA1 Is Essential for Efficient Basolateral Cholesterol Efflux during the Absorption of Dietary Cholesterol in Chickens. Journal of Biological Chemistry, 2003, 278, 13356-13366.	3.4	105
475	Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. Journal of Lipid Research, 2003, 44, 1470-1480.	4.2	85
476	A Role for Epsin N-terminal Homology/AP180 N-terminal Homology (ENTH/ANTH) Domains in Tubulin Binding. Journal of Biological Chemistry, 2003, 278, 28823-28830.	3.4	26
477	Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity. Journal of Biological Chemistry, 2003, 278, 13047-13055.	3.4	78
478	Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human Molecular Genetics, 2003, 12, 1555-1567.	2.9	713
479	Efflux and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1322-1332.	2.4	231
480	The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. Journal of Lipid Research, 2003, 44, 1251-1255.	4.2	40
481	Mutation Screening of the ALS2 Gene in Sporadic and Familial Amyotrophic Lateral Sclerosis. Archives of Neurology, 2003, 60, 1768.	4.5	40
482	Targeted disruption of Huntingtin-associated protein-1 (Hap1) results in postnatal death due to depressed feeding behavior. Human Molecular Genetics, 2002, 11, 945-959.	2.9	73
483	HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Human Molecular Genetics, 2002, 11, 2815-2828.	2.9	189
484	Protein Kinase A Site-specific Phosphorylation Regulates ATP-binding Cassette A1 (ABCA1)-mediated Phospholipid Efflux. Journal of Biological Chemistry, 2002, 277, 41835-41842.	3.4	116
485	Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease. Human Molecular Genetics, 2002, 11, 1939-1951.	2.9	129
486	Identification and functional analysis of a naturally occurring E89K mutation in the ABCA1 gene of the WHAM chicken. Journal of Lipid Research, 2002, 43, 1610-1617.	4.2	49

#	Article	IF	Citations
487	HIP1 and HIP12 Display Differential Binding to F-actin, AP2, and Clathrin. Journal of Biological Chemistry, 2002, 277, 19897-19904.	3.4	97
488	Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. Journal of Lipid Research, 2002, 43, 1939-1949.	4.2	26
489	Expression and Functional Analyses of Novel Mutations of ATP-Binding Cassette Transporter-1 in Japanese Patients with High-Density Lipoprotein Deficiency. Biochemical and Biophysical Research Communications, 2002, 290, 713-721.	2.1	30
490	Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. Journal of Lipid Research, 2002, 43, 1899-1907.	4.2	318
491	Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet, The, 2002, 359, 37-41.	13.7	186
492	Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease. Neuron, 2002, 33, 849-860.	8.1	553
493	Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease. Journal of Neuroscience, 2002, 22, 7862-7872.	3.6	344
494	Striatal neurochemical changes in transgenic models of Huntington's disease. Journal of Neuroscience Research, 2002, 68, 716-729.	2.9	88
495	High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clinical Genetics, 2002, 60, 198-205.	2.0	82
496	ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clinical Genetics, 2002, 61, 115-125.	2.0	95
497	ABCA1 mRNA and Protein Distribution Patterns Predict Multiple Different Roles and Levels of Regulation. Laboratory Investigation, 2002, 82, 273-283.	3.7	265
498	Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nature Cell Biology, 2002, 4, 95-105.	10.3	274
499	Mutant DNA-binding domain of HSF4 is associated with autosomal dominant lamellar and Marner cataract. Nature Genetics, 2002, 31, 276-278.	21.4	229
500	Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nature Genetics, 2002, 32, 326-330.	21.4	409
501	Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nature Neuroscience, 2002, 5, 731-736.	14.8	925
502	Structural and functional consequences of missense mutations in exon 5 of the lipoprotein lipase gene. Journal of Lipid Research, 2002, 43, 398-406.	4.2	30
503	Increased ABCA1 activity protects against atherosclerosis. Journal of Clinical Investigation, 2002, 110, 35-42.	8.2	216
504	Increased ABCA1 activity protects against atherosclerosis. Journal of Clinical Investigation, 2002, 110, 35-42.	8.2	121

#	Article	IF	Citations
505	Increased ABCA1 activity protects against atherosclerosis. Journal of Clinical Investigation, 2002, 110, 35-42.	8.2	57
506	The factor structure for positive and negative symptoms in South African Xhosa patients with schizophrenia. Schizophrenia Research, 2001, 47, 149-157.	2.0	42
507	Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population. Atherosclerosis, 2001, 156, 401-407.	0.8	35
508	Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease. Science, 2001, 293, 493-498.	12.6	1,191
509	Cloning and Characterization of Three Novel Genes, ALS2CR1, ALS2CR2, and ALS2CR3, in the Juvenile Amyotrophic Lateral Sclerosis (ALS2) Critical Region at Chromosome 2q33â€“q34: Candidate Genes for ALS2. Genomics, 2001, 71, 200-213.	2.9	46
510	Mutant Huntingtin Enhances Excitotoxic Cell Death. Molecular and Cellular Neurosciences, 2001, 17, 41-53.	2.2	173
511	A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nature Genetics, 2001, 29, 166-173.	21.4	635
512	Measurement of Mutational Flow Implies Both a High New-Mutation Rate for Huntington Disease and Substantial Underascertainment of Late-Onset Cases. American Journal of Human Genetics, 2001, 68, 373-385.	6.2	64
513	Wild-Type Huntingtin Reduces the Cellular Toxicity of Mutant Huntingtin In Vivo. American Journal of Human Genetics, 2001, 68, 313-324.	6.2	210
514	Onset and pre-onset studies to define the Huntingtonâ€™s disease natural history. Brain Research Bulletin, 2001, 56, 233-238.	3.0	43
515	Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13318-13323.	7.1	199
516	The â€˜flapâ€™ endonuclease gene FEN1 is excluded as a candidate gene implicated in the CAG repeat expansion underlying Huntington disease. Clinical Genetics, 2001, 59, 122-127.	2.0	35
517	The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clinical Genetics, 2001, 60, 293-300.	2.0	49
518	NMDA receptor function in mouse models of Huntington disease. Journal of Neuroscience Research, 2001, 66, 525-539.	2.9	246
519	Familial influence on age of onset among siblings with Huntington disease. American Journal of Medical Genetics Part A, 2001, 105, 399-403.	2.4	92
520	addendum: A one-hit model of cell death in inherited neuronal degenerations. Nature, 2001, 409, 542-542.	27.8	3
521	Human ABCA1 BAC Transgenic Mice Show Increased High Density Lipoprotein Cholesterol and ApoAI-dependent Efflux Stimulated by an Internal Promoter Containing Liver X Receptor Response Elements in Intron 1. Journal of Biological Chemistry, 2001, 276, 33969-33979.	3.4	176
522	HIP1 Functions in Clathrin-mediated Endocytosis through Binding to Clathrin and Adaptor Protein 2. Journal of Biological Chemistry, 2001, 276, 39271-39276.	3.4	174

#	Article	IF	Citations
523	Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Human Molecular Genetics, 2001, 10, 1531-1538.	2.9	103
524	Clinical markers of early disease in persons near onset of Huntingtonâ€™s disease. Neurology, 2001, 57, 658-662.	1.1	197
525	Common Genetic Variation inABCA1Is Associated With Altered Lipoprotein Levels and a Modified Risk for Coronary Artery Disease. Circulation, 2001, 103, 1198-1205.	1.6	280
526	Maternal expression of functional lipoprotein lipase and effects on body fat mass and body condition scores of mature cats with lipoprotein lipase deficiency. American Journal of Veterinary Research, 2001, 62, 264-269.	0.6	11
527	Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. Journal of Lipid Research, 2001, 42, 1717-1726.	4.2	244
528	The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 1811-1816.	7.1	89
529	Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Current Opinion in Lipidology, 2000, 11, 117-122.	2.7	111
530	Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clinical Genetics, 2000, 57, 1-10.	2.0	119
531	A one-hit model of cell death in inherited neuronal degenerations. Nature, 2000, 406, 195-199.	27.8	294
532	Michael Smith (1932â€“2000). Nature, 2000, 408, 786-786.	27.8	0
533	HIP12 is a non-proapoptotic member of a gene family including HIP1, an interacting protein with huntingtin. Mammalian Genome, 2000, 11, 1006-1015.	2.2	47
534	Wild-Type Huntingtin Protects from Apoptosis Upstream of Caspase-3. Journal of Neuroscience, 2000, 20, 3705-3713.	3.6	349
535	Huntingtin Interacting Protein 1 Induces Apoptosis via a Novel Caspase-dependent Death Effector Domain. Journal of Biological Chemistry, 2000, 275, 41299-41308.	3.4	108
536	Phenotypic Correction of Feline Lipoprotein Lipase Deficiency by Adenoviral Gene Transfer. Human Gene Therapy, 2000, 11, 21-32.	2.7	37
537	Huntingtin is required for normal hematopoiesis. Human Molecular Genetics, 2000, 9, 387-394.	2.9	40
538	Familial Aggregation of Psychotic Symptoms in Huntingtonâ€™s Disease. American Journal of Psychiatry, 2000, 157, 1955-1959.	7.2	61
539	Lipoprotein Lipase Activity Is Associated With Severity of Angina Pectoris. Circulation, 2000, 102, 1629-1633.	1.6	52
540	Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal Cells. Journal of Biological Chemistry, 2000, 275, 19831-19838.	3.4	320

#	Article	IF	Citations
541	Human huntingtin-associated protein (HAP-1) gene: genomic organisation and an intragenic polymorphism. Gene, 2000, 254, 181-187.	2.2	6
542	Predictive testing for Huntington's disease: the calm after the storm. Lancet, The, 2000, 356, 1944-1945.	13.7	43
543	Huntington disease: new insights on the role of huntingtin cleavage. , 2000, , 1-17.		28
544	Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. Journal of Lipid Research, 2000, 41, 521-531.	4.2	83
545	Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. Journal of Clinical Investigation, 2000, 106, 1263-1270.	8.2	295
546	Mutations du gÃ¨ne de l'ATP binding cassette-1 (ABC1) dans la maladie de Tangier et la dÃ©ficience familiale en HDL.. Medecine/Sciences, 2000, 16, 421.	0.2	0
547	An Actin-Binding Protein of the Sla2/Huntingtin Interacting Protein 1 Family Is a Novel Component of Clathrin-Coated Pits and Vesicles. Journal of Cell Biology, 1999, 147, 1503-1518.	5.2	202
548	Recent Insights into the Molecular Pathogenesis of Huntington Disease. Seminars in Neurology, 1999, 19, 385-395.	1.4	50
549	Cleavage of Atrophin-1 at Caspase Site Aspartic Acid 109 Modulates Cytotoxicity. Journal of Biological Chemistry, 1999, 274, 8730-8736.	3.4	99
550	A Frequent Mutation in the Lipoprotein Lipase Gene (D9N) Deteriorates the Biochemical and Clinical Phenotype of Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2708-2713.	2.4	32
551	In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. Human Molecular Genetics, 1999, 8, 25-33.	2.9	79
552	Accurate determination of the number of CAG repeats in the Huntington disease gene using a sequenceâ€specific internal DNA standard. Clinical Genetics, 1999, 55, 198-202.	2.0	32
553	A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study. Clinical Genetics, 1999, 55, 450-454.	2.0	109
554	Two common mutations (D9N, N291S) in lipoprotein lipase: a cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clinical Genetics, 1999, 56, 297-305.	2.0	46
555	Lipid and lipoprotein analysis of cats with lipoprotein lipase deficiency. European Journal of Clinical Investigation, 1999, 29, 17-26.	3.4	32
556	Kennedy's Disease. Journal of Neurochemistry, 1999, 72, 185-195.	3.9	211
557	Life Without Huntingtin. Normal Differentiation into FunctionalNeurons. Journal of Neurochemistry, 1999, 72, 1009-1018.	3.9	37
558	Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genetics, 1999, 22, 336-345.	21.4	1,609

#	Article	IF	Citations
559	Chromosomal localization of the Huntingtin Associated Protein (HAP-1) gene in mouse and humans with radiation hybrid and interspecific backcross mapping. Mammalian Genome, 1999, 10, 397-398.	2.2	5
560	Genomic organization of the human caspase-9 gene on Chromosome 1p36.1-p36.3. Mammalian Genome, 1999, 10, 757-760.	2.2	14
561	Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington's disease gene. Brain Research, 1999, 818, 468-479.	2.2	77
562	A Worldwide Assessment of the Frequency of Suicide, Suicide Attempts, or Psychiatric Hospitalization after Predictive Testing for Huntington Disease. American Journal of Human Genetics, 1999, 64, 1293-1304.	6.2	271
563	Forskolin and dopamine D1 receptor activation increase Huntingtin's association with endosomes in immortalized neuronal cells of striatal origin. Neuroscience, 1999, 89, 1159-1167.	2.3	45
564	A YAC Mouse Model for Huntingtonâ€™s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration. Neuron, 1999, 23, 181-192.	8.1	789
565	Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet, The, 1999, 354, 1341-1346.	13.7	345
566	Evidence for both nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington'sdisease in cell culture and in transgenic mice expressing mutant huntingtin. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 1047-1055.	4.0	29
567	Effect of concurrent LDL receptor gene and LPL gene mutations on LDL particles size, density and lipid composition. Atherosclerosis, 1999, 144, 175.	0.8	0
568	A Yeast Artificial Chromosome-Based Physical Map of the Juvenile Amyotrophic Lateral Sclerosis (ALS2) Critical Region on Human Chromosome 2q33â€“q34. Genomics, 1999, 55, 106-112.	2.9	18
569	Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. Journal of Lipid Research, 1999, 40, 735-743.	4.2	79
570	Cell death attenuation by `Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death and Differentiation, 1998, 5, 271-288.	11.2	293
571	Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nature Genetics, 1998, 18, 150-154.	21.4	456
572	Compound heterozygosity for frameshift mutations in the gene for lipoprotein lipase in a patient with early-onset chylomicronemia. Human Mutation, 1998, 11, S141-S144.	2.5	5
573	Dyslipidemias associated with heterozygous lipoprotein lipase mutations in the French-Canadian population. Human Mutation, 1998, 11, S148-S153.	2.5	14
574	Ile225Thr loop mutation in thelipoprotein lipase (LPL) gene is a de novo event. , 1998, 78, 313-316.		12
575	Gene structure and map location of the murine homolog of the Huntington-associated protein, Hap1. Mammalian Genome, 1998, 9, 565-570.	2.2	26
576	The new Clinical Genetics: towards the millennium. Clinical Genetics, 1998, 53, 1-2.	2.0	1

#	Article	IF	Citations
577	A novel Glu421Lys substitution in the lipoprotein lipase gene in pregnancy-induced hypertriglyceridemic pancreatitis. Clinica Chimica Acta, 1998, 269, 1-12.	1.1	40
578	A Huntington Diseaseâ€“Like Neurodegenerative Disorder Maps to Chromosome 20p. American Journal of Human Genetics, 1998, 63, 1431-1438.	6.2	64
579	The Influence of Huntingtin Protein Size on Nuclear Localization and Cellular Toxicity. Journal of Cell Biology, 1998, 141, 1097-1105.	5.2	300
580	A Common Mutation in the Lipoprotein Lipase Gene (N291S) Alters the Lipoprotein Phenotype and Risk for Cardiovascular Disease in Patients With Familial Hypercholesterolemia. Circulation, 1998, 97, 729-735.	1.6	80
581	Phenotypic Variation in Heterozygous Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 309-315.	2.4	128
582	Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract. Journal of Biological Chemistry, 1998, 273, 9158-9167.	3.4	499
583	The Asn9 variant of lipoprotein lipase is associated with the â€” 93G promoter mutation and an increased risk of coronary artery disease. Clinical Genetics, 1998, 53, 27-33.	2.0	5
584	The fatal attraction of polyglutamineâ€containing proteins. Clinical Genetics, 1998, 53, 233-242.	2.0	26
585	The Asn9 variant of lipoprotein lipase is associated with the -93G promoter mutation and an increased risk of coronary artery disease. Clinical Genetics, 1998, 53, 27-33.	2.0	41
586	Contribution of DNA Sequence and CAG Size to Mutation Frequencies of Intermediate Alleles for Huntington Disease: Evidence from Single Sperm Analyses. Human Molecular Genetics, 1997, 6, 301-309.	2.9	116
587	Pathological association and dissociation of functional systems in multiple sclerosis and Huntington's disease. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 63-76.	1.3	10
588	Assessment of French patients with LPL deficiency for French Canadian mutations.. Journal of Medical Genetics, 1997, 34, 672-675.	3.2	10
589	Segments in the C-terminal Folding Domain of Lipoprotein Lipase Important for Binding to the Low Density Lipoprotein Receptor-related Protein and to Heparan Sulfate Proteoglycans. Journal of Biological Chemistry, 1997, 272, 5821-5827.	3.4	48
590	Rethinking Genotype and Phenotype Correlations in Polyglutamine Expansion Disorders. Human Molecular Genetics, 1997, 6, 2005-2010.	2.9	132
591	Of molecular interactions, mice and mechanisms. Current Opinion in Neurology, 1997, 10, 291-298.	3.6	44
592	Efficient Adenovirus-Mediated Ectopic Gene Expression of Human Lipoprotein Lipase in Human Hepatic (HepG2) Cells. Human Gene Therapy, 1997, 8, 205-214.	2.7	11
593	Familial defective apolipoprotein B-100 in hypercholesterolemic Chinese Canadians: identification of a unique haplotype of the apolipoprotein B-100 allele. Atherosclerosis, 1997, 135, 181-185.	0.8	6
594	1.W05.3 Common mutations in the lipoprotein lipase gene influence plasma lipids and prevalence of coronary heart disease. Atherosclerosis, 1997, 134, 12.	0.8	0

#	Article	IF	Citations
595	1.P.265 Phenotypic variation in familial hypercholesterolemia: A comparison of Chinese patients heterozygous for the same or similar mutations in the low density lipoprotein-receptor gene living in China or Canada. Atherosclerosis, 1997, 134, 72.	0.8	0
596	2.W13.1 Molecular genetics as tools to redefine the clinics of lipoprotein disorders: The example of lipoprotein lipase deficiency. Atherosclerosis, 1997, 134, 110.	0.8	0
597	Risk Reversals in Predictive Testing for Huntington Disease. American Journal of Human Genetics, 1997, 61, 945-952.	6.2	34
598	Ethnic Variation and In Vivo Effects of the â^'93tâ†'g Promoter Variant in the Lipoprotein Lipase Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2672-2678.	2.4	40
599	Correction of Hypertriglyceridemia and Impaired Fat Tolerance in Lipoprotein Lipaseâ€"Deficient Mice by Adenovirus-Mediated Expression of Human Lipoprotein Lipase. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2532-2539.	2.4	58
600	HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nature Genetics, 1997, 16, 44-53.	21.4	353
601	Toward Understanding the Molecular Pathology of Huntington's Disease. Brain Pathology, 1997, 7, 979-1002.	4.1	69
602	Localization of the cell death genes CPP32 and Mch-2 to human Chromosome 4q. Mammalian Genome, 1997, 8, 56-59.	2.2	13
603	Interleukin-1Î±-converting enzyme (ICE) and related cell death genes ICErel-II and ICErel-III map to the same PAC clone at band 11q22.2-22.3. Mammalian Genome, 1997, 8, 611-613.	2.2	11
604	Dilemmas of anonymous predictive testing for Huntington disease: Privacy vs. optimal care. , 1997, 71, 197-201.		18
605	A single Ser259Arg mutation in the gene for lipoprotein lipase causes chylomicronemia in Moroccans of Berber ancestry. , 1997, 10, 179-185.		7
606	Differences in the Phenotype Between Children With Familial Defective Apolipoprotein B-100 and Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 826-833.	2.4	30
607	Genetic Variant Showing a Positive Interaction With Î²-Blocking Agents With a Beneficial Influence on Lipoprotein Lipase Activity, HDL Cholesterol, and Triglyceride Levels in Coronary Artery Disease Patients. Circulation, 1997, 95, 2628-2635.	1.6	117
608	Gene-based therapeutic strategies for Human Lipoprotein Lipase (LPL) deficiency: Rationale and prospects for alteration of atherogenic risk. Transfusion Science, 1996, 17, 79-87.	0.6	1
609	Huntington disease: new insights into the relationship between CAG expansion and disease. Human Molecular Genetics, 1996, 5, 1431-1435.	2.9	60
610	Compound heterozygosity for a known and a novel defect in the lipoprotein lipase gene (Asp250 ? Asn;) Tj ETQq0 0 0 rgBT /Overlock 10 189-195.	0.5	13
611	Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Lipids and Lipid Metabolism, 1996, 1302, 159-166.	2.6	101
612	A New Mutation Destroying Disulphide Bridging in the C-Terminal Domain of Lipoprotein Lipase. Biochemical and Biophysical Research Communications, 1996, 227, 189-194.	2.1	29

#	Article	IF	Citations
613	Update on genetics of Huntington's disease: availability of direct and accurate predictive test. Italian Journal of Neurological Sciences, 1996, 17, 185-187.	0.1	4
614	Patients' rights to laboratory data: Trinucleotide repeat length in Huntington disease. , 1996, 62, 6-9.		15
615	Auxiliary-directed peroxidation of 1,4-dienes. Tetrahedron, 1996, 52, 12381-12398.	1.9	8
616	Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract. Nature Genetics, 1996, 13, 442-449.	21.4	545
617	Absence of Disease Phenotype and Intergenerational Stability of the Cag Repeat in Transgenic Mice Expressing the Human Huntington Disease Transcript. Human Molecular Genetics, 1996, 5, 177-185.	2.9	109
618	Adverse psychological events occurring in the first year after predictive testing for Huntington's disease. The Canadian Collaborative Study Predictive Testing.. Journal of Medical Genetics, 1996, 33, 856-862.	3.2	55
619	Premature Atherosclerosis in Patients with Familial Chylomicronemia Caused by Mutations in the Lipoprotein Lipase Gene. New England Journal of Medicine, 1996, 335, 848-854.	27.0	286
620	Huntingtin Is Ubiquitinated and Interacts with a Specific Ubiquitin-conjugating Enzyme. Journal of Biological Chemistry, 1996, 271, 19385-19394.	3.4	313
621	Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Human Molecular Genetics, 1996, 5, 1875-1885.	2.9	94
622	The Asp ₉ Asn Mutation in the Lipoprotein Lipase Gene Is Associated With Increased Progression of Coronary Atherosclerosis. Circulation, 1996, 94, 1913-1918.	1.6	103
623	A mutation in the lipoprotein lipase gene is the molecular basis of chylomicronemia in a colony of domestic cats.. Journal of Clinical Investigation, 1996, 97, 1257-1266.	8.2	68
624	Hereditary Late-Onset Chorea Without Significant Dementia. Neurology, 1995, 45, 443-447.	1.1	56
625	Are we all of one mind? Clinicians' and patients' opinions regarding the development of a service protocol for predictive testing for Huntington disease. American Journal of Medical Genetics Part A, 1995, 58, 59-69.	2.4	24
626	Mapping of the gonadotropin-releasing hormone (GnRH) receptor gene to human Chromosome 4q21.2 by fluorescence in situ hybridization. Mammalian Genome, 1995, 6, 309-310.	2.2	10
627	A lipoprotein lipase mutation (Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nature Genetics, 1995, 10, 28-34.	21.4	235
628	Many roads lead to atheroma. Nature Medicine, 1995, 1, 22-23.	30.7	23
629	Mutations in the Gene for Lipoprotein Lipase. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1704-1712.	2.4	39
630	Patients With ApoE3 Deficiency (E2/2, E3/2, and E4/2) Who Manifest With Hyperlipidemia Have Increased Frequency of an Asn 291â†'Ser Mutation in the Human LPL Gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1695-1703.	2.4	59

#	Article	IF	Citations
631	Retroviral-Mediated Gene Transfer and Expression of Human Lipoprotein Lipase in Somatic Cells. Human Gene Therapy, 1995, 6, 853-863.	2.7	7
632	Ancestral differences in the distribution of the Î”2642 glutamic acid polymorphism is associated with varying CAG repeat lengths on normal chromosomes: insights into the genetic evolution of Huntington disease. Human Molecular Genetics, 1995, 4, 207-214.	2.9	74
633	Increased instability of intermediate alleles in families with sporadic Huntington disease compared to similar sized intermediate alleles in the general population. Human Molecular Genetics, 1995, 4, 1911-1918.	2.9	129
634	Somatic mosaicism in sperm is associated with intergenerational (CAG)n changes in Huntington disease. Human Molecular Genetics, 1995, 4, 189-195.	2.9	74
635	A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) contributes to the expression of familial combined hyperlipidemia. Human Molecular Genetics, 1995, 4, 1543-1549.	2.9	80
636	Origins and evolution of huntington disease chromosomes. Experimental Neurology, 1995, 4, 239-244.	1.7	25
637	Structural analysis of the 5â€² region of mouse and human huntington disease genes reveals conservation of putative promoter region and di- and trinucleotide polymorphisms. Genomics, 1995, 25, 707-715.	2.9	41
638	Genomic organization of the human Î±-adducin gene and its alternately spliced isoforms. Genomics, 1995, 25, 93-99.	2.9	37
639	Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell, 1995, 81, 811-823.	28.9	758
640	Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients. Atherosclerosis, 1995, 116, 153-162.	0.8	19
641	Sequence of the murine Huntington dusease gene: evidence for conservation, and polymorphism in a triplet (CCG) repeat alternate splicing. Human Molecular Genetics, 1994, 3, 85-92.	2.9	87
642	Analysis of DNA changes in the LPL gene in patients with familial combined hyperlipidemia.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1250-1257.	3.9	72
643	Sequence of the murine Huntington disease gene: evidence for conservation, alternate splicing and polymorphism in a triplet (CCG) repeat. Human Molecular Genetics, 1994, 3, 530-530.	2.9	30
644	Apolipoprotein CII-Padova (Tyr37-->stop) as a cause of chylomicronaemia in an Italian kindred from Siculiana.. Journal of Medical Genetics, 1994, 31, 622-626.	3.2	7
645	Homozygosity for a mutation in the lipoprotein lipase gene (Gly139?Ser) causes chylomicronaemia in a boy of Spanish descent. Human Genetics, 1994, 93, 339-343.	3.8	10
646	Recurrent missense mutations at the first and second base of codon Arg243 in human lipoprotein lipase in patients of different ancestries. Human Mutation, 1994, 3, 52-58.	2.5	25
647	Regional cerebral glucose metabolism in huntington's disease: A statistical investigation. Human Brain Mapping, 1994, 2, 95-102.	3.6	2
648	U-type exchange in a paracentric inversion as a possible mechanism of origin of an inverted tandem duplication of chromosome 8. American Journal of Medical Genetics Part A, 1994, 49, 384-387.	2.4	31

#	Article	IF	Citations
649	A CCG repeat polymorphism adjacent to the CAG repeat in the Huntington disease gene: implications for diagnostic accuracy and predictive testing. Human Molecular Genetics, 1994, 3, 65-67.	2.9	157
650	Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. American Journal of Cardiology, 1994, 73, 339-345.	1.6	78
651	Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nature Genetics, 1994, 6, 409-414.	21.4	383
652	A Worldwide Study of the Huntington's Disease Mutation: The Sensitivity and Specificity of Measuring CAG Repeats. New England Journal of Medicine, 1994, 330, 1401-1406.	27.0	563
653	Precise Mapping of the Brain Î±2-Adrenergic Receptor Gene within Chromosome 4p16. Genomics, 1994, 19, 298-302.	2.9	25
654	The Murine Homologues of the Huntington Disease Gene (Hdh) and the Î±-Adducin Gene (Add1) Map to Mouse Chromosome 5 within a Region of Conserved Synteny with Human Chromosome 4p16.3. Genomics, 1994, 22, 198-201.	2.9	21
655	Murine Î±-l-Iduronidase: cDNA Isolation and Expression. Genomics, 1994, 24, 311-316.	2.9	30
656	DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Human Molecular Genetics, 1994, 3, 2103-2114.	2.9	178
657	Issues in Molecular Genetic Testing of Individuals with Suspected Early-onset Familial AlzheimerÊ¼s Disease. Alzheimer Disease and Associated Disorders, 1994, 8, 116-125.	1.3	13
658	The molecular genetics of HuntingtonÊ¼s disease. Current Opinion in Neurology, 1994, 7, 325-332.	3.6	27
659	Gene environment interaction and plasma triglyceride levels: the crucial role of lipoprotein lipase. Clinical Genetics, 1994, 46, 15-18.	2.0	14
660	Normal CAG repeat length in the Huntington's disease gene in senile chorea. Neurology, 1994, 44, 2183-2183.	1.1	25
661	Reply to Dr. Kessler. American Journal of Medical Genetics Part A, 1993, 45, 696-697.	2.4	1
662	Diagnosis of Huntington disease: A model for the stages of psychological response based on experience of a predictive testing program. American Journal of Medical Genetics Part A, 1993, 47, 368-374.	2.4	34
663	South African founder mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia in the Dutch population. Human Genetics, 1993, 92, 567-570.	3.8	25
664	The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nature Genetics, 1993, 4, 398-403.	21.4	1,002
665	Molecular analysis of new mutations for Huntington's disease: intermediate alleles and sex of origin effects. Nature Genetics, 1993, 5, 174-179.	21.4	248
666	Identification of an Alu retrotransposition event in close proximity to a strong candidate gene for Huntington's disease. Nature, 1993, 362, 370-373.	27.8	50

#	Article	IF	Citations
667	Development of a program for identification of patients with familial hypercholesterolemia in British Columbia: A model for prevention of coronary disease. American Journal of Cardiology, 1993, 72, D25-D29.	1.6	6
668	Acidic and basic fibroblast growth factor-like immunoreactivity in the striatum and midbrain in Huntington's disease. Brain Research, 1993, 610, 1-7.	2.2	33
669	Mapping of the Human NMDA Receptor Subunit (NMDAR1) and the Proposed NMDA Receptor Glutamate-Binding Subunit (NMDARA1) to Chromosomes 9q34.3 and Chromosome 8, Respectively. Genomics, 1993, 17, 237-239.	2.9	19
670	Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Human Molecular Genetics, 1993, 2, 1535-1540.	2.9	189
671	A PCR method for accurate assessment of trinucleotide repeat expansion in Huntington disease. Human Molecular Genetics, 1993, 2, 635-636.	2.9	74
672	Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency. Lancet, The, 1993, 341, 1119-1121.	13.7	34
673	Monoamines and their metabolites in Huntington's disease brain: Evidence for decreased catechol-O-methyltransferase activity. Biological Psychiatry, 1993, 33, 551-553.	1.3	4
674	(CA)n-dinucleotide repeat at the PDEB locus in 4p16.3. Human Molecular Genetics, 1993, 2, 827-827.	2.9	7
675	A transcription map of the region containing the Huntington disease gene. Human Molecular Genetics, 1993, 2, 901-907.	2.9	42
676	AnAluelement retroposition in two families with Huntington disease defines a new activeAlusubfamily. Nucleic Acids Research, 1993, 21, 3379-3383.	14.5	49
677	Five year study of prenatal testing for Huntington's disease: demand, attitudes, and psychological assessment.. Journal of Medical Genetics, 1993, 30, 549-556.	3.2	96
678	George Huntington: the man behind the eponym.. Journal of Medical Genetics, 1993, 30, 406-409.	3.2	12
679	Differential 3â€² polyadenylation of the Huntington disease gene results in two mRNA species with variable tissue expression. Human Molecular Genetics, 1993, 2, 1541-1545.	2.9	94
680	Molecular analysis of late onset Huntington's disease.. Journal of Medical Genetics, 1993, 30, 991-995.	3.2	57
681	A 4 basepair deletion in exon 4 of the human lipoprotein lipase gene results in type I hyperlipoproteinemia. Human Molecular Genetics, 1993, 2, 1049-1050.	2.9	4
682	Familial predisposition to recurrent mutations causing Huntington's disease: genetic risk to sibs of sporadic cases.. Journal of Medical Genetics, 1993, 30, 987-990.	3.2	34
683	Phenotypic variation of mutations in the human lipoprotein-lipase gene. Biochemical Society Transactions, 1993, 21, 506-509.	3.4	17
684	The Psychological Consequences of Predictive Testing for HuntingtonÊ¼s Disease. Obstetrical and Gynecological Survey, 1993, 48, 248-250.	0.4	7

#	Article	IF	Citations
685	SORFIND: A COMPUTER PROGRAM THAT PREDICTS EXONS IN VERTEBRATE GENOMIC DNA. , 1993, , .		1
686	On planting alfalfa and growing orchids: the cloning of the gene causing Huntington disease. Clinical Genetics, 1993, 43, 217-222.	2.0	2
687	Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia. Archives of Internal Medicine, 1993, 153, 2349-2356.	3.8	18
688	Attitudes toward direct predictive testing for the Huntington disease gene. Relevance for other adult-onset disorders. The Canadian Collaborative Group on Predictive Testing for Huntington Disease. JAMA - Journal of the American Medical Association, 1993, 270, 2321-2325.	7.4	44
689	Recurrent pancreatitis and chylomicronemia in an extended Dutch kindred is caused by a Gly154â€“>Ser substitution in lipoprotein lipase.. Journal of Lipid Research, 1993, 34, 2109-2119.	4.2	26
690	Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease.. Journal of Clinical Investigation, 1993, 91, 677-683.	8.2	80
691	Gene-environment interaction in the conversion of a mild-to-severe phenotype in a patient homozygous for a Ser172-->Cys mutation in the lipoprotein lipase gene.. Journal of Clinical Investigation, 1993, 91, 1953-1958.	8.2	59
692	The prediction of exons through an analysis of spliceable open reading frames. Nucleic Acids Research, 1992, 20, 3453-3462.	14.5	77
693	The lipoprotein lipase Gly188----Glu mutation in South Africans of Indian descent: evidence suggesting common origins and an increased frequency.. Journal of Medical Genetics, 1992, 29, 119-122.	3.2	13
694	(CA)n-dinucleotide repeat polymorphism at the locus for the alpha2C adrenergic receptor (ADRA2C) on 4p16. Human Molecular Genetics, 1992, 1, 452-452.	2.9	9
695	Predictive testing for Huntington disease.. Journal of Medical Ethics, 1992, 18, 47-48.	1.8	3
696	The Psychological Consequences of Predictive Testing for Huntingtonâ€™s Disease. New England Journal of Medicine, 1992, 327, 1401-1405.	27.0	447
697	New Insights Into the Clinical Features, Pathogenesis and Molecular Genetics of Huntington Disease. Brain Pathology, 1992, 2, 321-335.	4.1	51
698	A missense mutation (Asp250â†'Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries. Genomics, 1992, 13, 649-653.	2.9	43
699	Nonrandom association between huntington disease and two loci separated by about 3 Mb on 4p16.3. Genomics, 1992, 13, 301-311.	2.9	31
700	The human Î²-subunit of rod photoreceptor cGMP phosphodiesterase: Complete retinal cDNA sequence and evidence for expression in brain. Genomics, 1992, 13, 698-704.	2.9	35
701	Mapping of the epitope on lipoprotein lipase recognized by a monoclonal antibody (5D2) which inhibits lipase activity. Lipids and Lipid Metabolism, 1992, 1128, 113-115.	2.6	49
702	Geographic distribution and genealogy of mutation 207 of the lipoprotein lipase gene in the French Canadian population of QuÃ©bec. Human Genetics, 1992, 89, 671-675.	3.8	35

#	Article	IF	Citations
703	Auxiliary-directed dioxygenation: stereoselective synthesis of a diene hydroperoxide. Tetrahedron Letters, 1992, 33, 443-446.	1.4	17
704	Exclusion of DNA changes in the Î²â€“subunit of the câ€“GMP phosphodiesterase gene as the cause for Huntington's disease. Nature Genetics, 1992, 1, 104-108.	21.4	12
705	Delineation of a 50 kilobase DNA segment containing the recombination site in a sporadic case of Huntington's disease. Nature Genetics, 1992, 2, 216-222.	21.4	7
706	A missense mutation Pro157Arg in lipoprotein lipase (LPLNijmegen) resulting in loss of catalytic activity. FEBS Journal, 1992, 208, 267-272.	0.2	18
707	Linkage studies and mutation analysis of the PDEB gene in 23 families with leber congenital amaurosis. Human Mutation, 1992, 1, 478-485.	2.5	6
708	Predictive testing for Huntington disease in Canada: The experience of those receiving an increased risk. American Journal of Medical Genetics Part A, 1992, 42, 499-507.	2.4	163
709	Predictive testing for Huntington disease in Canada: Adverse effects and unexpected results in those receiving a decreased risk. American Journal of Medical Genetics Part A, 1992, 42, 508-515.	2.4	225
710	Prevalence, geographical distribution and genealogical investigations of mutation 188 of lipoprotein lipase gene in the French Canadian population of QuÃ©bec. Clinical Genetics, 1992, 41, 206-210.	2.0	26
711	Cortical glucose metabolism in Huntington's disease. Neurology, 1992, 42, 223-223.	1.1	87
712	Identification of multiple CpG islands and associated conserved sequences in a candidate region for the Huntington disease gene. Genomics, 1991, 11, 1113-1124.	2.9	21
713	A low-copy repeat located in subtelomeric regions of 14 different human chromosomal termini. Cytogenetic and Genome Research, 1991, 57, 179-183.	1.1	12
714	Genetic variants affecting human lipoprotein and hepatic lipases. Current Opinion in Lipidology, 1991, 2, 104-109.	2.7	54
715	The FDG/PET Methodology for Early Detection of Disease Onset: A Statistical Model. Journal of Cerebral Blood Flow and Metabolism, 1991, 11, A96-A102.	4.3	37
716	Predictive testing for Huntington disease: Are we ready for widespread community implementation?. American Journal of Medical Genetics Part A, 1991, 40, 515-517.	2.4	17
717	Intrachromosomal location of the telomeric repeat (TTAGGG)n. Mammalian Genome, 1991, 1, 211-216.	2.2	28
718	Genomic organization and complete sequence of the human gene encoding the Î²-subunit of the cGMP phosphodiesterase and its localisation to 4p16.3. Nucleic Acids Research, 1991, 19, 6263-6268.	14.5	57
719	A polymorphic DNA marker at the D8S131 locus. Nucleic Acids Research, 1991, 19, 1725-1725.	14.5	0
720	A Mutation in the Human Lipoprotein Lipase Gene as the Most Common Cause of Familial Chylomicronemia in French Canadians. New England Journal of Medicine, 1991, 324, 1761-1766.	27.0	100

#	Article	IF	Citations
721	Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia.. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 290-297.	3.9	160
722	Amino acid substitution (Ile194---Thr) in exon 5 of the lipoprotein lipase gene causes lipoprotein lipase deficiency in three unrelated probands. Support for a multicentric origin.. Journal of Clinical Investigation, 1991, 87, 2005-2011.	8.2	69
723	Regional Cerebral Glucose Metabolism in Turner Syndrome. Canadian Journal of Neurological Sciences, 1990, 17, 140-144.	0.5	82
724	DNA testing for Huntington disease results in a modification of risk and not diagnosis of disease. European Journal of Pediatrics, 1990, 149, 513-513.	2.7	1
725	Characterization and organization of DNA sequences adjacent to the human telomere associated repeat (TTAGGG)n. Nucleic Acids Research, 1990, 18, 3353-3361.	14.5	57
726	A missense mutation at codon 188 of the human lipoprotein lipase gene is a frequent cause of lipoprotein lipase deficiency in persons of different ancestries.. Journal of Clinical Investigation, 1990, 86, 728-734.	8.2	157
727	Different options for prenatal testing for Huntington's disease using DNA probes.. Journal of Medical Genetics, 1989, 26, 353-357.	3.2	19
728	Non-random association between alleles detected at D4S95 and D4S98 and the Huntington's disease gene.. Journal of Medical Genetics, 1989, 26, 676-681.	3.2	75
729	Insurance and the Presymptomatic Diagnosis of Delayed-Onset Disease. JAMA - Journal of the American Medical Association, 1989, 262, 2384.	7.4	1
730	Predictive testing for Huntington disease: I. Description of a pilot project in British Columbia. American Journal of Medical Genetics Part A, 1989, 32, 211-216.	2.4	86
731	Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates. American Journal of Medical Genetics Part A, 1989, 32, 217-224.	2.4	141
732	Epiphyseal dysplasia, microcephaly, nystagmus, and retinitis pigmentosa. American Journal of Medical Genetics Part A, 1989, 33, 341-345.	2.4	14
733	Huntington disease: No evidence for locus heterogeneity. Genomics, 1989, 5, 304-308.	2.9	56
734	Silent periods, long-latency reflexes and cortical MEPs in Huntington's desease and at-risk relatives. Electroencephalography and Clinical Neurophysiology - Evoked Potentials, 1989, 74, 444-449.	2.0	48
735	A major insertion accounts for a significant proportion of mutations underlying human lipoprotein lipase deficiency.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 948-952.	7.1	110
736	Perinatal and first year followâ€up of patients with Praderâ€Willi syndrome: normal size of hands and feet. Clinical Genetics, 1989, 35, 161-166.	2.0	16
737	Sequence and expression of Tangier apoA-I gene. FEBS Journal, 1988, 173, 465-471.	0.2	30
738	A highly polymorphic locus very tightly linked to the Huntington's disease gene. Nature, 1988, 332, 734-736.	27.8	159

#	Article	IF	Citations
739	Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. Atherosclerosis, 1988, 73, 233-240.	0.8	11
740	Prenatal diagnosis of asplenia/polysplenia syndrome. American Journal of Obstetrics and Gynecology, 1988, 158, 1085-1087.	1.3	28
741	Presymptomatic Neuropsychological Impairment in Huntington's Disease. Archives of Neurology, 1988, 45, 769-773.	4.5	89
742	A polymorphic DNA probe located to human chromosome 4p16 (D4S62). Nucleic Acids Research, 1987, 15, 3938-3938.	14.5	5
743	Apolipoprotein B gene variants are involved in the determination of serum cholesterol levels: a study in normo- and hypelipidaemic individuals. Atherosclerosis, 1987, 67, 81-89.	0.8	165
744	Insufficient evidence to invoke defects in or around the A-I gene as the cause for familial hypoalphahpoproteinemia. Atherosclerosis, 1987, 67, 271-272.	0.8	0
745	A somatic cell hybrid panel for localizing DNA segments near the Huntington's disease gene. Genomics, 1987, 1, 29-34.	2.9	71
746	Cerebral Glucose and Dopa Metabolism in Movement Disorders. Canadian Journal of Neurological Sciences, 1987, 14, 448-451.	0.5	14
747	Preclinical testing in Huntington disease. American Journal of Medical Genetics Part A, 1987, 27, 733-734.	2.4	16
748	Ethical issues in preclinical testing in Huntington disease: Response to Margery Shaw's invited editorial comment. American Journal of Medical Genetics Part A, 1987, 28, 761-763.	2.4	4
749	Controlling for Cerebral Atrophy in Positron Emission Tomography Data. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 510-512.	4.3	11
750	Hypoalphalipoproteinemia Resembling Fish Eye Disease. Acta Medica Scandinavica, 1987, 221, 291-298.	0.0	25
751	Arrested Epidermal Morphogenesis in Three Newborn Infants With a Fatal Genetic Disorder (Restrictive Dermopathy).. Journal of Investigative Dermatology, 1987, 88, 330-339.	0.7	52
752	Regression Model for Predicting Dissociations of Regional Cerebral Glucose Metabolism in Individuals at Risk for Huntington's Disease. Journal of Cerebral Blood Flow and Metabolism, 1986, 6, 756-762.	4.3	19
753	Restrictive dermopathy: A newly recognized autosomal recessive skin dysplasia. American Journal of Medical Genetics Part A, 1986, 24, 631-648.	2.4	96
754	Cerebral metabolism of glucose in benign hereditary chorea. Movement Disorders, 1986, 1, 33-44.	3.9	40
755	Primary Lipoprotein Lipase Deficiency. , 1986, 201, 227-239.		25
756	Positron emission tomography in the early diagnosis of Huntington's disease. Neurology, 1986, 36, 888-888.	1.1	171

#	Article	IF	Citations
757	Deletion of Huntington's disease-linked G8 (D4S10) locus in Wolfâ€“Hirschhorn syndrome. Nature, 1985, 318, 75-78.	27.8	114
758	Urinary proteins in a patient with Tangier disease. Clinical Biochemistry, 1985, 18, 98-101.	1.9	3
759	Bilateral renal agenesis in twins. American Journal of Medical Genetics Part A, 1985, 21, 147-152.	2.4	5
760	Down's syndrome and Alzheimer's disease. Annals of Neurology, 1984, 16, 263-263.	5.3	1
761	Reflections on the history of Huntington's chorea. Trends in Neurosciences, 1983, 6, 122-124.	8.6	9
762	The high frequency of juvenile Huntington's chorea in South Africa. Journal of Medical Genetics, 1982, 19, 94-97.	3.2	21
763	Genetic aspects of Huntington's chorea: Results of a national survey. American Journal of Medical Genetics Part A, 1982, 11, 135-141.	2.4	17
764	Huntingtonâ€™s Chorea. , 1981, , .		246
765	Living with Huntingtonâ€™s Chorea: The Social Perspective. , 1981, , 123-135.		3